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ABSTRACT 
 
As the obesity epidemic increases, the prevalence of obesity-related diseases 
grows simultaneously. The internal environment of chronic low-grade inflammation, 
which characterizes obesity, leaves individuals vulnerable to disease. Cardiovascular 
dysfunction represents a consequential effect of obesity. An early indicator of 
cardiovascular disease is an impaired stress response. Further, the type of stress (active 
versus passive) may be differentially affected representing additional distinctions in 
impairment. In the present study, we have used two types of stress (active and passive) to 
investigate obesity-instigated alterations in cardiovascular, immune and endocrine 
response to stress. In addition, we have evaluated how these systems may overlap to 
perpetuate a potentially damaging stress response.  
Based on correlations used to determine relationships among the cardiovascular, 
immune and endocrine system we found that obese and non-obese groups responded 
similarly to active stress. However, the obese group exhibited blunted cardiovascular 
recovery following active stress. Conversely, the obese and non-obese groups responded 
differently to passive stress with the obese group demonstrating an overall greater stress 
response. This response included exaggerated reactivity of both the cardiovascular and 
endocrine systems. This suggests a possible link in obese individuals between the 
sympathetic nervous system and the hypothalamic-pituitary-adrenal axis when activated 
in response to passive stress. These results indicate that the presentation of an abnormal 
stress response may occur at different times based on the type of stress. In response to 
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passive stress, obese individuals show an exaggerated stress response; whereas the 
impairment associated with active stress appears during recovery. 
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I. INTRODUCTION 
Obesity 
Obesity is a rapidly spreading epidemic associated with devastating health 
complications including an increased risk for premature death (Katzmarzyk, Janssen, & 
Ardern, 2003). Approximately 2.8 million deaths are attributed to obesity each year, 
making obesity the “fifth leading risk for global deaths.” (WHO, 2013). Worldwide more 
than one in 10 adults are considered obese (defined as having a body mass index ≥ 30). 
The United States has one of the highest concentrations of obesity in the world, with 
more than one-third of the adult population considered obese. According to the Centers 
for Disease Control and Prevention in 2008, the medical costs associated with obesity 
were estimated at $147 billion (Finkelstein, Trogdon, Cohen, & Dietz, 2009). 
Obesity arises from an imbalance between energy consumption and expenditure. 
The availability of food with poor nutritional value and high caloric content coupled with 
the increasingly sedentary lifestyle that predominates American life serves as the impetus 
that propels the obesity epidemic. Although obesity is found in all nations, nationalities 
and economic groups, some disparities do exist. In the United States, the obesity 
epidemic appears concentrated in the southeastern region. This overlaps the area that has 
been identified as the “stroke belt” and later the “diabetes belt” due to the increased 
prevalence of these diseases (Borhani, 1965; Barker, Kirtland, Gregg, Geiss, & 
Thompson, 2011).   
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Excess weight, being the trademark of obesity, exerts considerable influence over 
many of the body’s biological systems. This multi-system involvement has linked obesity 
to a number of debilitating and mortal disease states. This list includes the leading cause 
of death worldwide, heart disease, which in the United States accounted for 596,339 
deaths in 2011, approximately one in four (Hoyert & Xu, 2012). The pathology of obesity 
has been shown to increase the likelihood of other vascular complications including 
stroke, hypertension, diabetes, dyslipidemia, atherosclerosis and peripheral vascular 
disease (Abel, Litwin, & Sweeney, 2008; Kenchaiah et al., 2002; Lakka, Lakka, Salonen, 
Kaplan, & Salonen, 2001; Mensah, 2004; Stapleton, James, Goodwil, & Frisbee, 2008; 
Wang & Nakayama, 2010; Wilson, D'Agostino, Sullivan, & Parise, 2002). 
Obesity and the Cardiovascular System 
Hypertension, or high blood pressure, is arguably the most recognized risk factor 
for cardiovascular disease. This recognition may be attributed to its prevalence, with an 
estimated one in three Americans suffering from hypertension. The number of individuals 
receiving treatment is much lower because there are no outward symptoms of 
hypertension, which is why it has been deemed the “silent killer” (CDC, 2013). An 
individual’s blood pressure is represented by two values labeled systolic and diastolic. 
Systolic blood pressure indicates the maximum amount of pressure in the arteries 
corresponding to contraction of the heart, and diastolic blood pressure is measured when 
the heart is at rest and the pressure in the arteries is at its lowest.  
Obesity has been shown to contribute to hypertension in multiple ways. One 
purpose of the circulatory system is to deliver oxygen rich blood, which provides 
nutrients to all of the tissues in the body. When an individual accumulates excess adipose 
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tissue the circulatory system, primarily the heart, must compensate for the additional 
mass by increasing the pressure in the system to ensure all tissues receive adequate blood 
perfusion. When deoxygenated blood returns to the heart it enters the right atrium and 
follows a path through the lungs to be oxygenated, the blood then returns to the heart and 
is pumped by the left ventricle through the aorta to reenter the vascular system. In obese 
individuals cardiac adaptations must be made to meet the increased metabolic demand. 
Increased cardiac output is achieved in obese individuals by a more forceful contraction 
of the left ventricle. Over time the left ventricle hypertrophies, or becomes enlarged 
(Levy et al., 1988). This alteration in the myocardium known as left ventricular 
hypertrophy is often found in combination with hypertension in obese individuals 
(Paunovic, Jakovljevic, & Stojanov, 2006). 
The heart is not the only organ that may undergo structural changes instigated by 
obesity. Another mechanism through which obesity contributes to hypertension is by 
alteration of the vascular structure. Many obese individuals also suffer from 
hyperlipidemia, or high levels of lipids (fats) in the blood (Boyd, Koenigsberg, Falkner, 
Gidding, & Hassink, 2005; Paccaud, Schlüter-Fasmeyer, Wietlisbach, & Bovet, 2000). 
This condition is more commonly referred to as high triglycerides or high cholesterol. 
Clinically, cholesterol is quantified as high-density lipoprotein and low-density 
lipoprotein. When levels of low-density lipoproteins are elevated these proteins begin to 
migrate into the vascular tissue that makes up the inner most lining of the blood vessel, 
the endothelium. As the proteins accumulate, they form plaques that cause a narrowing of 
the lumen, or diameter of the vessel (for a review see, Moreno & Mitjavila, 2003). This 
process, which results in atherosclerosis, can have various detrimental outcomes defined 
 4 
by the location of damage in the body. If the blood vessels supplying the heart are 
affected the individual may suffer from coronary heart disease, if the vessels to the brain 
are affected it is termed cerebrovascular disease, or if it is the vessels to the legs, 
peripheral vascular disease. An additional consequence of atherosclerosis is a stiffening 
of the vessel, which impedes vasodilatation (Cox et al., 1989). Vasodilatation and 
constriction are mechanisms by which blood pressure is regulated. When blood vessels 
are unable to dilate effectively, pressure in the circulatory system increases, leading to 
hypertension.  
Despite the negative consequences of obesity, including tissue and vascular 
remodeling, an extensive amount of research has shown that these changes are not 
irreversible. Several studies have demonstrated a reversal of many of these alterations 
following weight loss (MacMahon, Wilcken, & Macdonald, 1986; Reisin et al., 1983; 
Ziccardi et al., 2002). To lose weight an individual must modify their lifestyle such that 
the energy they are expending exceeds the energy they consume as food. There are 
countless reasons people continue to gain or maintain excess adipose tissue. One 
explanation suggested by emerging research is that an individual’s reaction to stress may 
play a role in maintaining and perhaps contributing to obesity (Björntorp, 2001). It has 
been well established that irregular cardiovascular functioning in response to stress is 
predictive of future cardiovascular disease (Obrist, 1981). Increasing evidence suggests 
obesity may be characterized by cardiovascular dysregulation in response to stress 
(Carroll, Phillips, & Der, 2008; Phillips, 2011). Further, different types of stress may 
elucidate distinct mechanisms for the resulting dysregulation.   
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A potential mediator of this dysregulation and the vascular damage that is often 
associated with obesity are cytokines. Cytokines are signaling molecules secreted by 
adipose tissue, many of which promote inflammation and contribute to abnormal 
endothelial functioning (Calabro, Chang, Willerson, & Yeh, 2005). Cytokines are potent 
effectors of the immune system and serve as regulators of the stress response. The 
mechanisms by which cytokines promote inflammation and their relationship with 
cardiovascular dysfunction will be the focus of the following sections.  
The role that adipose tissue plays in chronic inflammation lends to its importance 
as an independent risk factor in cardiovascular dysfunction. The current study seeks to 
further establish the relationship between obesity and cardiovascular dysfunction and 
investigate the role of obesity in immune dysfunction. This will be the first study to 
examine immunoregulatory alterations in obese individuals following different types of 
laboratory stress. 
Obesity Induced Inflammation 
Obesity is characterized by an excess of adipose tissue. Adipose tissue was once 
thought to be a passive organ, used as a storage device for triglycerides that could be 
reabsorbed into the blood stream at times of energy depletion. It is now known that 
adipose tissue, composed mostly of adipocytes (i.e., fat cells), secretes a number of 
cytokines that promote inflammation (Berg & Scherer, 2005; Van Gaal, Mertens, & 
Block, 2006). This inflammation contributes to both cardiovascular and immune 
dysregulation.  
Zhang et al. (1994) is often credited as opening the door for adipocyte 
endocrinology with the identification of adipose tissue as the source of the hormone 
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leptin. Adipose tissue has also been implicated in immunomodulation through the 
secretion of proinflammatory cytokines and the presence of immune cells in adipose 
tissue. Adipose tissue falls into two main categories: white adipose tissue and brown 
adipose tissue. The latter plays a role in thermogenesis, particularly in newborns, and 
until recently was thought to be almost non-existent in adults. Emerging evidence 
suggests not only the existence of brown adipose tissue in adults but also its potential role 
in weight loss. Although brown and white adipose tissue share a number of 
characteristics, brown adipose tissue does not appear to contribute to the inflammation 
present in obese individuals and may even provide some protection to the vascular 
system during inflammation (Fitzgibbons et al., 2011). Conversely, white adipose tissue, 
which exists in much greater prevalence, appears to be the bedrock of systemic 
inflammation. 
White adipose tissue is composed primarily of adipocytes. As an individual 
consumes more calories than they expend, the adipocytes expand to accommodate the 
surplus of energy. In addition, more adipocytes are manufactured and infiltration by 
macrophages occurs. Macrophage cells are pervasive in adipose tissue and contribute 
significantly to the production of proinflammatory cytokines (Weisberg et al., 2003). In 
healthy individuals, these cytokines are released upon detection of a foreign invader. 
They work to promote inflammation that activates and directs the immune system to 
combat the threat. A recent review echoes the conclusion of numerous studies over the 
last two decades, “chronic tissue inflammation, particularly in adipose tissue, has been 
considered as a key underlying mechanism for the development of obesity-related 
metabolic syndrome” (Xu, 2013, p. 21).  
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Prior to the discovery of cytokine secretion by adipose tissue, clinicians became 
aware of a clustering of metabolic abnormalities that seemed to promote cardiovascular 
disease. These risk factors include high blood pressure, elevated blood sugar (a symptom 
of insulin resistance), dyslipidemia and obesity. According to the International Diabetes 
Federation, one in four adults worldwide suffer from metabolic syndrome. Until recently, 
the classification of what disorders constituted metabolic syndrome remained an issue of 
debate. In 2006, a workshop was held and a committee was formed to establish the 
worldwide definition of metabolic syndrome (Alberti, Zimmet & Shaw, 2006). 
According to this definition, an individual must exhibit central obesity and two of the 
following four symptoms to be diagnosed with metabolic syndrome: high blood pressure, 
elevated triglycerides, low high-density lipoprotein or elevated blood sugar. The 
committee also established the “platinum standard” representing the paradigm for a 
research diagnosis of metabolic syndrome that includes additional features. One of these 
additional features is confirmation of an inflammatory state, evidenced by elevated 
proinflammatory cytokines.  
Obesity, through a path of inflammation, has been linked to all of the other 
features of the metabolic syndrome. As described in the previous section, obesity 
increases blood pressure by a number of mechanisms including a reduction in lumen 
diameter and hardening of the vasculature. These structural changes to the vasculature 
result in part from elevated blood lipids. Obesity is often accompanied by dyslipidemia, 
specifically elevated triglycerides and low high-density lipoproteins. Adipose cells are 
storages sites for excess triglycerides. When an individual consumes food, the level of 
circulating triglycerides increases; between meals, the stored triglycerides are released 
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into the blood stream through hormonal signaling. Hypertriglyceridemia is a condition 
often found in correlation with obesity where circulating levels of triglycerides are above 
a normal range. High-density lipoproteins are considered the “good” cholesterol. In 
contrast to low-density lipoproteins, which circulate through the body and in high 
concentrations can form plaques, high-density lipoproteins are thought to transport excess 
cholesterol from the blood to the liver where it can be recycled or broken down to be 
excreted from the body. Thus, a decrease in the concentration of high-density lipoproteins 
has obvious consequences. The perpetrator behind this reduction in high-density 
lipoproteins is unknown, however evidence indicates elevated cytokine production may 
be partially responsible (Zuliani et al., 2007). 
Elevated blood glucose occurs naturally following food consumption. As glucose 
levels increase, the pancreas releases the hormone insulin into the blood. Insulin 
facilitates glucose metabolism and storage. Therefore, in the presence of insulin, levels of 
glucose in the blood will typically decrease. In some individuals, the tissues in the body 
no longer respond to insulin and as a result, blood sugar remains elevated. This inability 
of the body to respond to insulin is known as insulin resistance. The pancreas, unaware of 
the insulin resistance, though sensitive to the rise in glucose, will continue to secrete 
insulin leading to a state of hyperinsulinemia. The co-occurrence of hyperinsulinemia and 
obesity is well known, however the direction of this relationship has not been established. 
An analysis of data from The Bogalusa Heart Study demonstrated a temporal relationship 
between obesity and hyperinsulinemia (Srinivasan, Myers, & Berenson, 1999). Obesity, 
as measured by baseline body mass index, was able to predict subsequent 
hyperinsulinemia, suggesting that obesity precedes insulin resistance.  
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In addition to regulating glucose, insulin plays a direct role in lipid storage. Fats 
that are ingested are broken down by pancreatic lipase into free fatty acids and glycerol, 
which can be further broken down into glucose. Once out of the digestive system, some 
of the free fatty acids and glycerol are recombined into triglycerides. As insulin rises in 
response to increased glucose, it activates adipocytes to secrete lipoprotein lipase; this 
enzyme promotes the break down of triglycerides in the bloodstream and the absorption 
of free fatty acids into adipocytes, where they are stored as triglycerides. Through the 
stimulation of lipoprotein lipase, insulin acts as a gatekeeper. When insulin levels are 
high, adipocytes are able to take up and store lipids from the blood. Moreover, in an 
attempt to lower blood sugar, insulin also prevents the break down of lipids stored by 
adipose tissue thereby preventing weight loss. Thus, it is likely that insulin resistance, 
besides providing some impetus for obesity, also contributes to a perpetual state of 
adipose retention. 
Many proinflammatory cytokines are elevated in obese individuals. Several of 
these cytokines have been linked to other symptoms of the metabolic syndrome. Two 
cytokines that are elevated in obese individuals and demonstrate instigation of metabolic 
functioning are interleukin-1β and interleukin-6. Interleukin-1β belongs to a group of 
cytokines know as the interleukin-1 family. This family of interleukins is able to regulate 
the immune response by binding to their receptor. The family contains proinflammatory 
cytokines such as interleukin-1α and interleukin-1β as well as an endogenous antagonist 
known an interleukin-1 receptor antagonist.  
Interleukin-1β is elevated in obese compared to non-obese individuals (Moschen 
et al., 2011; Speaker, & Fleshner 2012). Adipose tissue has been shown to be a source of 
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interleukin-1β (Juge-Aubry et al., 2003; Lagathu et al., 2006). In a study of 21 obese 
patients undergoing laparoscopic adjustable gastric banding, pre- and post-weight loss 
levels of interleukin-1β were assessed (Moschen et al., 2011). Six months following the 
surgery, adipose tissue concentrations of interleukin-1β decreased significantly. This 
drop in interleukin-1β was accompanied by an increase in insulin sensitivity when 
compared to sensitivity prior to weight loss.  
The effect of interleukin-1β on glucose regulation has been extensively studied. 
Clinical evidence substantiating this relationship revealed the effect of interleukin-1 
blockade on glycemic control. Larsen and colleagues (2007) performed a double-blind, 
placebo-controlled study to evaluate the effect of anakinra (an interleukin-1 receptor 
antagonist) in patients with type 2 diabetes. Elevated levels of glucose in the blood 
characterize type 2 diabetes. This elevation is caused by an individual’s inability to 
produce enough insulin or a decline in the tissues responsiveness to insulin (i.e., insulin 
resistance). At the end of the 13 week study, participants who had undergone treatment 
with anakinra exhibited an increase in glycemic control as measured by glycated 
hemoglobin level. The researchers attributed this outcome to an increase in pancreatic 
beta-cell functioning. Beta-cells are located in the islets of Langerhans within the 
pancreas and are responsible for the production of insulin. An in vitro study utilizing 
isolated rat islets of Langerhans directly assessed the effect of interleukin-1 on beta-cells 
(Mandrup-Poulsen et al., 1986). The investigators incubated the isolated islets for six 
days in multiple concentrations of interleukin-1. Following the incubation period, the 
culture medium was analyzed for the presence of insulin and islets were examined for 
decomposition. A dose-dependent reduction was found in both insulin production and 
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disintegration of the islets. This study provides evidence of the damaging effects of 
interleukin-1 on beta-cells and the ensuing deficit of insulin.  
The permanence of the damage to islets caused by exposure to interleukin-1β is 
currently under debate. Researchers have found that the resiliency of beta-cells is 
dependent on the duration of exposure to interleukin-1β (Scarim, Heitmeier, & Corbett, 
1997), the concentration of interleukin-1β (Spinas et al., 1986), and whether the beta-
cells are active at the time of exposure to interleukin-1β, measured by concurrent 
exposure to glucose (Palmer et al., 1989). Owyang et al. (2010) found that the 
impairment resulting from exposure to interleukin-1β can be prevented and even reversed 
through the actions of interleukin-1β antibodies. In a mouse model of diet-induced 
obesity prophylactic treatment with XOMA 052, an anti-interleukin-1β antibody, was 
able to improve glucose tolerance, insulin secretion and sensitivity. Unlike anakinra, 
which inhibits the action of interleukin-1β by competitively binding to its receptor, 
XOMA 052 binds to interleukin-1β directly, thereby reducing the affinity for its receptor 
(Owyang et al., 2011). Thus, XOMA 052 does not interfere with the actions of the other 
interleukin-1 family members, interleukin-1α or interleukin-1 receptor antagonist. 
Treatment with XOMA 052 that occurs in tandem with diet-induced obesity is of limited 
clinical significance. Because of the initial absence of noticeable symptoms of health 
deterioration resulting from obesity, patients fail to seek early intervention. Noting this 
discrepancy, the investigators included a treatment group that “better reflects the situation 
of an [already] overweight patient with progressing T2DM” (Owyang et al., 2010). In this 
group, beginning at six weeks of age, mice were given a high fat diet to promote obesity. 
Prior to the initiation of treatment at 10 weeks, mice were evaluated and in addition to 
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obesity displayed impaired glucose tolerance, elevated glucose, impaired insulin 
production and reduced insulin sensitivity. Mice were then treated with XOMA 052 for 
nine weeks while continuing the high fat diet. At 19 weeks, mice treated with XOMA 
052 demonstrated improved glucose tolerance, a decrease in circulating glucose and 
improved insulin production and sensitivity.  
In addition to the recovery of glucose regulation in obese mice treated with 
XOMA 052, improvements in the levels of triglycerides, free fatty acids and cholesterol 
were also seen when compared to control mice (Owyang, et al., 2010). The ability of 
XOMA 052 to enhance lipid regulation in obesity makes it a potential candidate for the 
treatment of cardiovascular disease. Currently, work is being done to assess the efficacy 
of XOMA 052 in animal models of atherosclerosis (Bhaskar et al., 2011). Another drug 
that inhibits interleukin-1β, Canakinumab, is currently in phase III of clinical trials. 
Unlike XOMA 052, which inhibits through allosteric binding, Canakinumab prevents 
activation through competitive binding to interleukin-1β (Blech et al., 2012). Thus, 
interleukin-1β cannot be bound to Canakinumab and its receptor. This clinical trial, set to 
conclude in 2016, is evaluating three doses of Canakinumab in the prevention of 
cardiovascular events in patients who have already experienced a myocardial infarction. 
This study includes a number of secondary objectives. One is to quantify the progression 
of atherosclerosis through the monitoring of arterial plaque accumulation. Another 
secondary objective is to evaluate the effect of Canakinumab on glucose regulation. 
Patients with a preexisting diagnosis of type 2 diabetes will be monitored for changes in 
insulin secretion and sensitivity. An additional outcome measure of Canakinumab’s 
effect on glucose regulation will be the time to a diagnosis of type 2 diabetes in patients 
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who, at the time of enrollment in the study, had a diagnosis of pre-diabetes. Successful 
completion of this trial may provide additional evidence for the influence of interleukin-
1β in the progression of atherosclerosis and type 2 diabetes. Moreover, this study could 
offer insight into a potential new therapy for diseases resulting from unrestrained 
inflammation. 
Interleukin-1β has been found to act in concert with other cytokines, even 
promoting their release in some instances. In vitro incubation of human adipocytes for 
four hours with interleukin-1β stimulated the release of interleukin-6 (Flower, Gray, 
Pinkney, & Mohamed-Ali, 2003). The expression of interleukin-6 by adipocytes has been 
found by others; additionally, in vivo evidence shows elevated levels of interleukin-6 in 
obese compared to non-obese individuals (Weisberg et al., 2003; Roytblat et. al, 2000).  
Elevated plasma levels of interleukin-6 have demonstrated an active role in 
vascular dysfunction (Stapelton, James, Goodwil, & Frisbee, 2008). In a study of 508 
healthy, middle-aged men elevated blood pressure predicted high levels of interleukin-6 
after controlling for age and other cardiac risk factors (Chae, Lee, Rifai, & Ridker, 2001). 
Interestingly, the relationship between blood pressure and interleukin-6 showed a linear 
trend even in groups without hypertension. In other words, even in the absence of 
hypertension, increased levels of interleukin-6 correlated with elevated blood pressure. 
Another study by Bautista et al. (2004) found similar results; however, when the 
researchers divided the study population into quartiles based on level of interleukin-6, 
they found the relationship between elevated blood pressure and interleukin-6 may not be 
linear. After controlling for traditional cardiovascular risk factors and the presence of 
other cytokines, they found a three-fold increase in the likelihood of having hypertension 
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for participants in the second quartile when compared to the first. Participants in the third 
and fourth quartiles were slightly more than two times as likely to have hypertension than 
participants in the first quartile. These findings suggest elevated levels of interleukin-6 
increase the likelihood of having hypertension, however, continued escalation of 
interleukin-6 may not have an additive effect on the likelihood of hypertension. 
One potential mechanism for the relationship between interleukin-6 and 
hypertension is the renin-angiotensin aldosterone system (RAAS). This system is 
responsible for the regulation of blood pressure and tissue perfusion through its influence 
on vascular resistance; disruption of this system has long been implicated in 
cardiovascular disorders. Renin is released primarily from the kidneys and stimulates the 
production of angiotensin I from angiotensinogen. Angiotensin I is then converted by 
angiotensin converting enzyme into angiotensin II. Angiotensin II is able to increase 
blood pressure through a number of mechanisms including: stimulation of the adrenal 
glands to release aldosterone, which increases blood volume; vasoconstriction; 
stimulation of the pituitary gland to secrete vasopressin; enhanced activity of the 
sympathetic nervous system and hypertrophy of the vascular wall and the left ventricle 
(for a review of the actions of angiotensin II on the cardiovascular system see Fyhrquist, 
Metsärinne, & Tikkanen, 1995). 
The mechanisms responsible for the release of renin and thus the cascade of the 
RAAS are not well understood. Although the primary activation of this system likely 
takes place within the kidney, catecholamines have been shown to promote the release of 
renin through β-adrenergic activation, suggesting a mechanism of neural control. The 
RAAS also influences inflammation, specifically, angiotensin II promotes the synthesis 
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of interleukin-6 (Funakoshi, Ichiki, Ito, & Takeshita, 1999). The correlation between the 
presence of interleukin-6 and hypertension led researchers to examine the role of 
interleukin-6 in hypertension. Angiotensin II is a known promoter of hypertension; this 
led researchers to speculate that interleukin-6 may mediate the effect of angiotensin II in 
the development of hypertension. In a study using mice that lacked the gene responsible 
for the production of interleukin-6 and a control group, researchers administered high 
doses of angiotensin II (Lee et al., 2006). The investigators found that in both groups 
angiotensin II significantly increased blood pressure. However, this increase in blood 
pressure was significantly less in the interleukin-6 knockout mice. This suggests that 
interleukin-6 is able to exacerbate the hypertensive effect of angiotensin II.  
In addition to its influence on hypertension, interleukin-6 may also instigate other 
features of the metabolic syndrome. Rats given increasing doses of interleukin-6 revealed 
a dose-dependent elevation in triglycerides (Nonogaki et al., 1995). The resulting 
hypertriglyceridemia suggests that interleukin-6 may have a role in lipid metabolism. In a 
study of 112 women, level of interleukin-6 was positively correlated with body mass 
index, waist circumference, blood pressure and triglycerides, and negatively correlated to 
level of high-density lipoprotein and insulin sensitivity (Piché et al., 2005). 
Consequently, the women with increased adiposity exhibited elevated levels of 
interleukin-6, hypertriglyceridemia and low levels of high-density lipoproteins.  
Much of the research that has been conducted investigating the influence of 
interleukin-6 on lipid metabolism has been correlational. Not much is known about the 
direction of the relationship or the specific mechanisms behind the dysregulation that 
often accompanies elevated levels of interleukin-6. One theory to explain the rise in lipid 
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levels is that interleukin-6 decreases lipoprotein lipase. Lipoprotein lipase is one of the 
mechanisms used to clear excess triglycerides from the blood stream by promoting its up-
take and storage. Evidence for this hypothesis comes from a study showing a decrease in 
lipoprotein lipase activity in adipose tissue samples taken from obese participants after 
the samples were exposed to recombinant human interleukin-6 (Trujillo et al., 2004). 
Additional evidence comes from a study using an animal model. In 1976, Kompiang, 
Bensadoun and Yang administered an anti-lipoprotein lipase serum to roosters. After only 
30 minutes from the time of the injection, there was a rise in circulating triglycerides. 
This inhibition of lipoprotein lipase may also be responsible for the decrease in 
the plaque clearing, high-density lipoproteins. Goldberg et al. (1990) designed a study to 
elucidate the relationship between level of circulating high-density lipoproteins and 
lipoprotein lipase activity. They found that the availability of an essential structural 
component of high-density lipoprotein, apolipoprotein A1, is decreased in response to 
inhibition of lipoprotein lipase. This finding lends evidence to the hypothesis that 
elevations in interleukin-6 may be responsible for both the low levels of high-density 
lipoproteins and the elevated triglycerides through a reduction in lipoprotein lipase. An 
epidemiological study of 1044 older adults evaluated the relationship between circulating 
levels of high-density lipoproteins and inflammatory markers (Zuliani et al., 2007). The 
researchers found that an elevated level of interleukin-6 was the strongest predictor of 
low high-density lipoprotein. 
Mounting evidence now supports the view of obesity being a state of chronic 
systemic inflammation. This inflammation is considered to be at the root of many of 
obesity’s co-morbidities. Collectively termed the metabolic syndrome, high blood 
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pressure, elevated blood sugar and dyslipidemia work to promote cardiovascular 
dysfunction often leading to debilitating disease states. A mediator in this relationship 
between obesity and cardiovascular dysfunction appears to emerge from an immune 
system gone awry. One consequence of this malfunctioning immunomodulation is the 
elevation in circulating cytokines originating from the excess adipose tissue. The 
complicit role of cytokines in the progression of cardiovascular dysfunction is still under 
investigation. An early indicator of cardiovascular disease is an impaired stress response. 
Despite the volumes of research on stress reactivity, relatively little has been done with 
specific attention to immune dysregulation in obese populations. The current study 
investigates the role that obesity plays in immune dysregulation and the impact on 
cardiovascular dysfunction. 
Stress Response 
Chronic stress is often a poorly defined construct in cardiovascular physiology 
research that typically involves psychosocial factors. Chronic stress is commonly 
characterized in the literature on cardiovascular reactivity as being social or 
environmental. However, chronic stress of physical origin may provide new insight into 
impaired cardiovascular functioning. The current study operationalizes chronic stress as 
obesity.  
When presented with a stressor, the autonomic nervous system (ANS) and 
hypothalamic-pituitary-adrenal (HPA) axis are often activated simultaneously (Chida & 
Hamer, 2008). Björntorp (2001) gives a thorough description of the process of HPA 
activation. HPA activation in humans stimulates the production of cortisol from the 
adrenal glands, which then binds to glucocorticoid receptors. Stimulation of lipoprotein 
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lipase activity is seen with increases in cortisol (Ottosson, Vikman-Adolfsson, Enerback, 
Olivecrona, & Björntorp, 1994). Lipoprotein lipase, when found in adipose tissue, acts as 
a catalyst for fat storage. Higher concentrations of glucocorticoid receptors in visceral 
rather than peripheral adipose tissue leads to a rise in cortisol binding in the visceral 
tissue. This binding leads to an increase in lipoprotein lipase activity, resulting in 
accumulation of visceral adipose tissue, at the site of higher glucocorticoid receptor 
expression. 
One consequence of the circular relationship between cortisol production and 
visceral adipose tissue expansion is undefined causality. It may be speculated that 
glucocorticoid receptor prevalence in existing adipose tissue leads to a cycle of continued 
increase in adiposity. Alternatively, a state of chronic stress lends evidence to a 
preexisting condition of impaired stress reactivity or recovery predating that of obesity. 
The current study will not be longitudinal and therefore cannot directly address causation 
between obesity and impaired stress response. Instead, this study will focus on 
differences in the cardiovascular response to stress in obese and non-obese individuals 
taking into account the influence of HPA activation by assessing baseline and reactivity 
concentrations of cortisol. 
Cortisol, which is known as “the stress hormone,” exhibits a diurnal pattern with 
concentrations being highest soon after waking and dropping off later in the day. This 
hormone serves a number of regulatory functions including: glucose metabolism, blood 
pressure regulation and immunoregulation. An excess of cortisol or hypercortisolism is 
the driving force behind Cushing’s syndrome. In these patients, prolonged exposure to 
excess cortisol leads to a state of obesity. When treated, cortisol levels return to normal 
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and the obesity is often resolved (Styne, Grumbach, Kaplan, Wilson, & Conte, 1984). In 
obese populations, cortisol is often found to be produced and secreted in excess; 
however, the concentrations in circulation are normal or low in comparison to normal 
weight participants (Björntorp, & Rosmond, 2000). This discrepancy may arise from 
more rapid cortisol clearing seen in conjunction with elevated adiposity. A consequence 
of excess adipose tissue is elevated glucocorticoid receptor expression, with more 
receptors to bind to, cortisol will predictably be removed from circulation at a higher rate.  
While often acting in tandem with the HPA axis following stress, study of the 
ANS has entertained a greater body of research. The ANS can be subdivided into the 
sympathetic nervous system and parasympathetic nervous system. Each of these 
subdivisions plays a vital role in stress response and recovery. Quick and sufficient 
response to stress is an integral part of survival and imperative to human health. 
Complications in this continuum of activation and recovery can lead to damaging 
consequences. The role of the stress response and cardiovascular function will be the 
focus of the next section. 
Reactivity Hypothesis 
When presented with a stressful situation, generalized arousal is often helpful in 
managing the stressor. In some people, the arousal or reactivity of the sympathetic 
nervous system is greater than what is thought to be normal. Cardiovascular reactivity is 
classically defined as the change from a resting or baseline state to one of psychological 
or physical challenge. The reactivity hypotheses as conceptualized by Obrist (1981) 
suggest exaggerated physiological response to acute stressors could lead to 
cardiovascular dysfunction such as hypertension or coronary heart disease. Several 
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studies confirm a large cardiovascular response to acute stress as a risk factor for 
cardiovascular disease (Lovallo & Gerin, 2003; Matthews, 2004; Schwartz, 2003). The 
reactivity hypothesis has found support in obese populations (Silva, 2009; Steptoe, 2005; 
Voudoukis, 1970) with some evidence pointing to central obesity as the mediating factor 
(Davis & Twamley, 1999; Davy & Hall, 2004).  
HPA activation in response to stress is also altered by excess adiposity. Although 
obese participants may not show elevated HPA activity during rest, when exposed to a 
stressor activation of the HPA axis as measured by cortisol exceeds the reactivity of 
normal weight participants (Björntorp, 1997). Some researchers have found that in 
participants with obesity, an exaggerated sympathetic response to stress may be 
intertwined with a correspondingly enlarged HPA response (Pasquali et al., 1996). 
Extended elevations of cortisol can produce hypertension in humans (Kelly, Mangos, 
Williamson, & Whitworth, 1998). Not surprisingly, patients with Cushing’s syndrome are 
at an increased risk for cardiovascular disease-related mortality (Mancini, Kola, Mantero, 
Boscaro, & Arnaldi, 2004). An interesting finding is that elevated cortisol may predict a 
cardiovascular related death even in the absence of preexisting cardiovascular disease 
(Vogelzangs et al., 2010).   
Blunted Reactivity 
More recent findings suggest that it is not only an exaggerated response that may 
be harmful, as suggested by the reactivity hypotheses, but that blunted reactivity to stress 
may also be considered dysfunctional. Blunted reactivity is characterized by a diminished 
cardiovascular response from baseline to change produced by an acute stressor. Blunted 
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reactivity has been found in obese subjects, such that as body mass index increased, heart 
rate response to acute stress decreased (Carroll, Phillips, & Der, 2008; Phillips, 2011).  
Finding both an increase and a decrease in physiological response to acute 
stressors in obese subjects may seem to create a confound. However, a recent 
comprehensive review of the literature by Lovallo (2010) clarifies why this dichotomy 
may exist. Lovallo points out a common theme in the literature where, until recently, a 
large physiological response was thought to lead to complications whereas a smaller 
response is healthier. The review indicates the importance of examining exaggerated as 
well as diminished physiological reactions to stress as potential indicators of poor health 
outcomes. That is, an intermediate degree of cardiovascular response to stressors may be 
most adaptive in dealing with environmental events. Too much or too little response may 
be maladaptive and associated with negative health outcomes. Interestingly, the negative 
health outcomes may differ depending on which end of the continuum the reactivity falls.  
As described above, an exaggerated cardiovascular response to stress is associated 
with subsequent hypertension and other risk factors for cardiovascular disease. 
Alternatively, a blunted cardiovascular response to stress appears to be an indicator of 
other types of negative health consequences. Bulimia nervosa is a psychological disorder 
characterized by extreme overeating followed by intense feelings of guilt and subsequent 
destructive behaviors that are meant to alleviate guilt such as crash dieting, excessive 
exercise and purging of food. Four criteria must be met for a diagnosis of bulimia 
nervosa: repeated binged eating, repeated compensatory behaviors subsequent to binge 
eating, persistence of above symptoms at least twice a week for three months and an 
undue influence of weight on self image (American Psychiatric Association, 2000). In a 
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study by Koo-Loeb, Pedersen and Girdler (1998), the cardiovascular reactivity of 15 
women with a diagnosis of bulimia nervosa were compared to 15 controls. Baseline 
values of blood pressure and heart rate revealed no differences in cardiovascular function 
at rest. However, during stress tasks participants with bulimia nervosa exhibited a 
decreased blood pressure and heart rate response that appeared to be somewhat 
influenced by level of anxiety.  
More recent investigation has linked blunted reactivity to poorer cognitive ability, 
depression, obesity and self-reported health (Ginty, Phillips, Roseboom, Carroll, & 
deRooij, 2012; Phillips, 2011). Three measures of cognitive ability were found to be 
related to blunted cardiovascular response to stress, such that individuals with poorer 
cognitive ability demonstrated a reduced cardiovascular reactivity to stress (Ginty et al., 
2012). The relationship between systolic blood pressure and heart rate maintained 
significance for all three measures of cognitive ability even after controlling for 
confounders (e.g., baseline values, education, age and body mass index). Blunted 
diastolic reactivity remained significant for two of the three cognitive ability measures 
after confounders were entered; however, significance was attenuated for the third 
cognitive measure. Some researchers have suggested a relationship between cognitive 
ability and depression, such that depression is predictive of impaired cognitive 
functioning (Rabbitt, Donlan, Watson, McInnes, & Bent, 1995; Ravnkilde et al., 2002; 
Strömgren, 1977).  
Emerging evidence indicates a relationship between depression and blunted 
cardiovascular reactivity. In 2007, data from 1608 adults were examined for an 
association between depressive symptoms and cardiovascular reactivity (Carroll, Phillips, 
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Hunt, & Der, 2007). A correlation was found between depression and blunted reactivity 
(systolic blood pressure and heart rate). A regression analysis that controlled for baseline 
values, age and body mass index found that depression was still significantly related to 
blunted systolic and heart rate reactivity. As a follow up to this study in 2011, researchers 
evaluated the predictive ability of blunted reactivity on future depression (Phillips, Hunt, 
Der, & Carroll, 2011). They found that blunted heart rate reactivity to stress was 
predictive of depression five years later. This diminished reactivity to stress is a relatively 
new concept and therefore lacks the longitudinal support for relationships that can be 
found between hyperreactivity and later disease states. Nonetheless, the studies currently 
available offer new insight into the paradox of cardiovascular reactivity and the negative 
health consequences. These findings alter some initial presumptions of a monotonic 
relationship between reactivity and disease that originated from the reactivity hypothesis. 
Instead of exaggerated or blunted reactivity, an intermediate degree of cardiovascular 
response to stressors may be most adaptive in dealing with environmental events. Thus, 
future studies should examine stress response on a continuum where response on either 
end of the normative distribution should be evaluated as possibly problematic.   
In addition to a diminished response of the sympathetic nervous system, blunting 
of the HPA axis in response to stress has also been found in connection with adverse 
health conditions. This reduction in HPA response to stress has been linked to other 
conditions also characterized by blunted sympathetic activity such as eating disorders and 
diminished cognitive ability (Ginty, Phillips, Higgs, Heaney, & Carroll, 2012; Ginty, 
Phillips, Roseboom, Carroll, & deRooij, 2012). Impaired HPA response has also been 
found in individuals with an impaired immune response and autoimmune diseases; 
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personality traits such as neuroticism and a decrease in openness; and stress-related 
disorders such as posttraumatic stress syndrome, chronic fatigue syndrome, fibromyalgia 
and rheumatoid arthritis (Buske-Kirschbaum, von Auer, Krieger, Weis, Rauh, & 
Hellhammer, 2003; Buske-Kirschbaum, Ebrecht, & Hellhammer, 2010; Heim, Ehlert, & 
Hellhammer, 2000; Oswald et al., 2006; Sternberg, 1997).  
In some instances, obesity appears to inhibit HPA reactivity as measured by a 
reduction in cortisol (Salehi, Ferenczi, & Zumoff, 2005). Prior to the release of cortisol, 
corticotrophin releasing hormone is secreted by the hypothalamus which then stimulates 
the adrenal glands to produce cortisol. Some researchers have suggested that obese 
individuals have a diminished response to the actions of corticotrophin releasing 
hormone. In an investigation of 10 obese women and seven controls, peak cortisol levels 
were reduced in the obese women following administration of corticotrophin releasing 
hormone (Kopelman et al., 1988). In addition to blunted cortisol reactivity to stress, 
baseline levels of cortisol may also be reduced in obese individuals due to elevated levels 
of leptin. As mentioned previously leptin is released from adipose tissue, further it 
appears in elevated concentrations in correlation with obesity (Considine et al., 1996). An 
in vitro analysis of the effects of Leptin on adrenocortical cells revealed inhibitory 
properties (Bornstein, Uhlmann, Haidan, Ehrhart-Bornstein, & Scherbaum, 1997). 
Following a 24-hour incubation period with leptin, cells were stimulated with 
corticotrophin releasing hormone. The incubated cells demonstrated a blunted response to 
corticotrophin manifest by reduced cortisol production. This action of leptin has been 
replicated (Pralong et al., 1998); however these findings must be taken with caution in 
regards to their application to obese populations. In human obesity, elevated leptin often 
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results from leptin resistance. Therefore, the actions of leptin on adrenal tissue in obese 
individuals may be compromised, as is the case with other tissues in the body.  
Recovery from Stress 
A person’s reactivity to stress is undoubtedly important in creating a picture of 
cardiovascular health; nevertheless, it may not be telling the whole story. Although 
working together the HPA axis and ANS can produce helpful responses to stress that 
allow for quick, efficient resolve of the stressor, problems occur when these systems 
work in sustaining the stress response. The importance of the stress response should not 
overshadow the significance of effective recovery following the termination of a stressor. 
A review of the literature suggests that recovery from stress may help illuminate a 
disturbance of cardiovascular functioning, even when reactivity does not appear to yield 
impairments. Recovery is measured as the time it takes to return to baseline levels of 
cardiovascular functioning once a psychological or physical challenge has ended.  
A meta-analysis by Chida and Hamer (2008) demonstrated that general life stress 
resulted in slowed recovery from laboratory stressors. Exposure to chronic stress has also 
been associated with poor recovery (Gump & Matthews, 1999; Lepore, Miles, & Levy, 
1997). Impaired recovery has been positively correlated with obesity, when reactivity 
showed no relationship (Brydon, 2011). Further, results suggest subjects who are more 
obese or those with greater abdominal obesity are at an increased risk of recovery 
impairment (Steptoe, 2005). Although a return to individual baseline parameters will 
eventually occur, the inadequate recovery results in an overexposure to stress hormones, 
leading to adipose tissue accumulation and excessive demands on the cardiovascular 
system.  
 26 
Immune Response 
In 1975, Robert Ader coined the term psychoneuroimmunology. Prior to Ader’s 
research, the immune system was thought to act autonomously; however, his studies 
demonstrated that the immune system could be trained to respond through classical 
conditioning. This revolutionary finding came as a surprise to Ader and Cohen (1975) as 
they investigated taste aversion through classical conditioning in rats. The rats were 
injected with Cytoxan, a drug that causes stomach upset and has immunosuppressive 
effects, as they drank a saccharin solution. The rats began to associate the saccharin with 
the aversive effects of the Cytoxan and begin to avoid the saccharin. The avoidance 
continued after the administration of Cytoxan had stopped. In an attempt to reverse the 
aversion, the rats were force-fed the saccharin solution and in theory should have 
“learned” that they were no longer experiencing the unpleasant effects of Cytoxan. 
Unexpectedly, several of the rats died. Ader and Cohen hypothesized, and later 
confirmed, that the immune system had been conditioned and immunosuppression could 
be instigated by environmental stimuli. The field that has grown out of this seminal 
finding encompasses interactions and relationships between an individual’s perceptions 
and behavior and their endocrine, nervous and immune systems.  
The stress response is an adaptive mechanism meant to provide support to 
different systems in the body when an individual is dealing with disruptions to 
homeostasis, perceived as a potential threat. Activation of the sympathetic nervous 
system allows almost instantaneous alterations in cardiac, vascular, respiratory and 
digestive systems, commonly referred to as the fight or flight response. These changes in 
response to stress occur through the release of catecholamines, namely norepinephrine 
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and epinephrine, which then bind to adrenergic receptors on various cells in the affected 
organ system. Stress induced activation of the HPA axis occurs through the release of 
corticotrophin releasing hormone by the hypothalamus, which then acts on the anterior 
pituitary to produce and release adrenocorticotropic hormone. The resulting cascade 
culminates in the production and secretion of glucocorticoids by the adrenal glands, the 
most recognized being cortisol (Björntorp, 2001). Not unlike the sympathetic response to 
stress, activation of the HPA axis primes the body for action. For example cortisol, by up-
regulating glucose metabolism, increases blood sugar levels providing the energy 
required to overcome the stressor. Glucocorticoid levels are controlled through a 
negative-feedback loop whereby circulating levels of cortisol inhibit the release of 
corticotrophin releasing hormone, thereby regulating the duration and magnitude of the 
HPA axis stress response. 
Both the sympathetic and HPA systems have bidirectional relationships with the 
immune system, meaning they are both influenced by and exert influence over the 
immune system. Further, these systems are influenced by the nature and magnitude of the 
immune response. Much of the communication between these systems occurs via the 
signaling proteins known as cytokines. In a comprehensive review of neuroimmune 
modulation, Elenkov and colleagues (2000) describe a number of studies confirming 
these relationships. The sympathetic nervous system is able to activate the immune 
system through sympathetic innervation of various immune organs and through activation 
of adrenergic receptors located on the surface of many immune cells. Sympathetic 
activation has heterogeneous effects on the adaptive immune system; it is generally 
accepted that cellular immunity is suppressed while humoral immunity may be enhanced 
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(Elenkov & Chrousos, 1999). These shifts in immunity reflect alterations in cytokine 
profiles, commonly represented as Th1 (cellular) and Th2 (humoral).  
The adaptive immune system has evolved to defend against several types of 
invaders or pathogens including: bacteria, viruses, fungi and parasites (Sompayrac, 
2003). Depending on the type of pathogen (intracellular versus extracellular) and the 
physiological state of the host, the immune system will be directed to produce either Th1 
or Th2 cytokines. The “classical” Th1 cytokines are tumor necrosis factor – β, interferon 
– γ and interleukin – 2. These cytokines work together to defend against attacks by 
intracellular pathogens. Further, they also inhibit the production of Th2 cytokines. Th2 
cytokines defend against extracellular pathogens such as certain bacteria and parasites. 
These cytokines, interleukins – 4, 5 and 13, antagonize Th1 cytokines (Sompayrac, 
2003). Interleukin – 5 promotes the production of immunoglobulin A, an antibody that 
will be discussed in more detail later. 
Given their mutually antagonistic properties, both Th1 and Th2 cytokines can be 
considered pro- and anti-inflammatory depending upon the disease process being 
considered. Immune dysregulation causing a persistent shift in either direction for an 
extended period of time could result in various immune based diseases. For example, an 
overactive Th1 response is associated with inflammation and autoimmune diseases such 
as rheumatoid arthritis. Conversely, diseases like asthma and allergies are associated with 
Th2 polarization. Chronic stress-mediated activation of the HPA axis has a parallel effect 
on the adaptive immune system, with a shift towards Th2 dominance. Thus, the previous 
view that stress results almost exclusively in immunosuppression has been revised to 
reflect the alterations that stress has on immune regulation. Short-term activation of the 
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stress response may be beneficial by reducing inflammation, through inhibition of Th1 
cytokines. However, if the stress response is exaggerated or prolonged, the ensuing 
suppression of inflammatory Th1 cytokines can leave the individual vulnerable to both 
infection and (because of the loss of Th1/Th2 balance) development of Th2 mediated 
hypersensitivity diseases such as allergy, asthma and systemic lupus erythematosus. 
Equally as detrimental, understimulation or a blunted immune response to stress with 
subsequent insufficient Th2 cytokine production may result in unnecessary inflammation 
that could manifest as an autoimmune disease (for a review see, Marshall, 2011). 
As signalers of innate immunity, interleukin-1β and interleukin-6 can be 
differentially affected by stress following activation of the sympathetic nervous system 
and HPA axis. Catecholamines that are released following sympathetic nervous system 
stimulation have been associated with the up-regulation of proinflammatory cytokines 
(Papanicolaou et al., 1996). In contrast, activation of the HPA axis has restrictive effects 
on the innate immune response, given that the release of glucocorticoids results in 
inhibition of both interleukin-1β and interleukin-6 (Kovalovsky, Refojo, Holsboer, & 
Arzt, 2000; Waage, Slupphaug, & Shalaby, 1990). These differential effects of stress on 
innate immunity again emphasize that stress is not universally immunosuppressive, but 
represents modulation of immune activity. Chronic disruption to immunoregulation 
through an impaired response to stress will likely have detrimental health outcomes.  
In a reciprocal manner, there is evidence that the immune system modulates the 
activity of the sympathetic nervous system through a feedback mechanism utilizing 
cytokines. Upon detection of threats to homeostasis, interleukin-1β and interleukin-6 are 
released as first responders and defense signals of the immune system. These cytokines 
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initiate a cascade, mobilizing other participants in the immune response. Further, they are 
able to activate both the sympathetic nervous system and HPA axis (Besedovsky del Rey, 
Sorkin, & Dinarello, 1986; Chrousos, 2000). One function of the stress response is to 
generate the energy needed to overcome the stressor. Therefore, activation of the stress 
response by the immune system may represent a mechanism for the individual to produce 
the energy required to defend against pathogens (for a review see, Maier, 2003). This co-
activation is considered adaptive in dealing with short-term stress, however this 
arrangement may become maladaptive when dealing with chronic stress. For instance, the 
cytokine-mediated activation of the HPA axis obstructs the system’s internal negative 
feedback mechanism meant to regulate the stress response. This could result in a 
prolonged HPA activation and elevated levels of cortisol. Both excess cortisol and 
chronic stress have been linked to cardiovascular dysfunction and obesity (Björntorp, 
2001; Mancini et al., 2004; Styne et al., 1984).   
As will be discussed in detail below, there is a large body of evidence 
demonstrating that external stressors are able to alter the cardiovascular and immune 
system. Much of what has been discussed as the immune response to stress thus far has 
been what is considered a normal response. Adipose tissue, once thought to be 
hormonally inert, is now considered a potent endocrine organ, which can have a direct 
effect on an individual’s physiological response to stress. Thus, it may be hypothesized 
that individuals with excess adipose tissue are at an increased risk for additional signaling 
processes that may interfere with what has evolved as the most advantageous stress 
response. 
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Indeed, a number of studies have shown that both interleukin-1β and interleukin-6 
are secreted by adipose tissue. Increasing evidence suggests these cytokines may be 
involved in the inflammatory process that link obesity and vascular dysfunction (Calabro, 
Chang, Willerson, & Yeh, 2005). Thus, the relationship between obesity and impaired 
cardiovascular response may be mediated by elevated cytokines and prolonged, 
unnecessary activation of the stress response. Additional measurements are needed to test 
this hypothesis. Good candidates include measurement of cortisol to evaluate degree and 
duration of HPA activation as well as measures of specific cytokines that are members of 
the interleukin family and have been linked to obesity, specifically interleukin-1β and 
interleukin-6 (Kirschbaum & Hellhammer, 1989; Speaker & Fleshner, 2012; Yudkin, 
Kumari, Humphries & Mohamed-Ali, 2000). 
Differences in Reaction to Active vs Passive Stress 
There are many dimensions used to classify different types of stressors: sensory 
intake versus sensory avoidance, active versus passive, or psychological versus physical. 
These dimensions are not meant to be exclusive. There is considerable overlap between 
these distinctions; often the terms will be used interchangeably. The present study 
examined the active/passive and psychological/physical dimensions of two stress tasks. 
The differences in response and recovery to different types of laboratory stressors 
uncover differences in the cardiovascular pathways activated, as manifested in different 
hemodynamic patterns being elicited by different types of stressors. Researchers in the 
field of immunology have also utilized different types of stress tasks and have been 
successful in finding variations in immune reactivity based on task. The current study 
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utilized two laboratory stressors that, according to the literature, elicit different immune 
and hemodynamic patterns of response.  
Cardiovascular Differences 
Sharpley and Gordon (1999) demonstrated a difference in the cardiovascular 
patterns initiated by the mental arithmetic (MA) versus the cold pressor (CP) task. The 
results showed that the MA task elicited a sharp heart rate increase in the first thirty 
seconds of the task followed by a gradual decrease. The CP task showed a smaller heart 
rate increase that was maintained over the course of the task. These tasks have also been 
found to elicit different responses in blood pressure that will be described in more detail 
below. There is some consensus in the literature that the CP and MA tasks activate 
different pathways (Allen, Obrist, Sherwood, & Crowell, 1987; Andrén & Hannson, 
1981, Gianaros & Sheu, 2009, Obrist, 1981; Willemsen et al., 1998). The attempts made 
to describe the mechanisms responsible for differences in pathways of response have not 
reached a consensus.  
In a review of the literature, Gianaros and Sheu (2009) examine possible pathway 
differences that would explain the divergence of cardiovascular response. The CP task is 
a physical stressor that requires passive coping. The vascular resistance or 
vasoconstriction that occurs in response to temperature results in stimulation of α-
adrenergic receptors. There appears to be agreement in the literature that α-adrenergically 
mediated vasoconstriction leads to an increase in total peripheral resistance (Allen et al., 
1987; Andrén & Hannson, 1981; Willemsen et al., 1998).  
The increase in total peripheral resistance resulting from α-adrenergic receptor 
activation is speculated to lead to a rise in diastolic but not systolic blood pressure 
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(Willemsen et al., 1998). Others have found a rise in both systolic and diastolic blood 
pressure following the CP task (Allen et al., 1987; Andrén & Hannson, 1981). The rise in 
systolic blood pressure could also be the result of an increase in heart rate (Allen et al., 
1987) although some suggest there is actually a decrease in heart rate following the CP 
task (Willemsen et al., 1998). The possible increase in heart rate may be mediated by 
activation of β-adrenergic receptors (Allen et al., 1987; Sherwood, Allen, Obrist, & 
Langer, 1986). However, others suggest the CP task does not elicit a β-adrenergic 
response (Matthews, 2004). Speculation has also arisen about possible desensitization of 
β-adrenergic receptors in participants under chronic stress resulting in higher baseline 
levels of sympathetic activity (Benschop et al., 1994).  
It is speculated that participants engage in active coping when presented with the 
MA task, which is considered a psychological stressor. During this task, increases in 
vascular resistance are seen in parallel with increases in heart rate. There is not complete 
agreement in the literature, but several studies have suggested these responses originate 
from both α and β-adrenergic receptor stimulation (Allen et al., 1987; Gianaros & Sheu, 
2009; Willemsen et al., 1998).  
Alpha-adrenergic receptors activated in response to the MA task are thought to 
result in vasoconstriction of peripheral vessels. This may contribute to increases seen in 
both systolic and diastolic blood pressure following the MA task (Phillips, 2011; 
Willemsen et al., 1998). However, myocardial β-adrenergic receptor activation may have 
a larger role in increasing heart rate due to the negligible changes in total peripheral 
resistance (Allen et al., 1987, Andrén & Hannson, 1981).  
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Relatively few studies have examined the early warning signs of impaired 
cardiovascular reactivity and recovery in obese populations. Results from many of the 
studies are mixed regarding cardiovascular measures and obesity, yet there seems to be 
some consistent effects. Baseline levels of blood pressure have been found to be higher in 
obese participants. Thus, controlling for baseline levels of cardiovascular functioning is a 
critical component for comparisons between tasks (Brydon, 2011; Carroll, Phillips & 
Der, 2008, Phillips, 2011; Steptoe, 2005). 
Heart rate reactivity appears to be negatively correlated with body mass index, 
suggesting blunted cardiac reactivity in obese participants (Carroll, et al., 2008; Phillips, 
2011). However, obesity seems to have an exaggerated effect on blood pressure 
reactivity. This heightened reactivity seems to be a function of an increase in diastolic 
blood pressure. More specifically, central adiposity may be a greater risk factor for 
exaggerated reactivity than is peripheral adiposity (Davis & Twamley, 1999; Steptoe, 
2005). There is evidence to suggest systolic blood pressure reactivity may be blunted in 
obese participants (Carroll et al., 2008).  
Measures of recovery have been neglected in many studies investigating obesity 
and cardiovascular reactivity. In studies where this information was considered, a delay 
in diastolic blood pressure recovery was demonstrated in obese subjects, specifically 
those with greater abdominal obesity (Brydon, 2011; Steptoe, 2005). The reasons for 
these differences in obese subjects are not fully understood.  
Immune Differences 
Similar to the cardiovascular response, the immune response to stress is 
dependent on the type of stress. Laboratory stress has been shown to alter immune 
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response in both animals (Moynihan, 2003) and humans (Xiang, Del Ben, Rehm, & 
Marshall, 2011). The MA and CP tasks have been used to find differential effects of 
stress on immune response. Stress induced activation of the sympathetic nervous system 
and HPA axis have a direct role in immunomodulation. This should not be surprising 
given that stress is the term used to describe the body’s reaction to a threat to homeostasis 
and the immune system is activated in response to threat from “foreign” invaders. This 
illustrates one point of contact between the stress response and the immune response. 
When the body detects a foreign invader, it responds by promoting the release of 
interleukin-1β and interleukin-6. These signaling molecules then promote a stress 
response through activation of the sympathetic nervous system and HPA axis. 
Interleukin-1β was one of the first cytokines to be discovered (Dinarello, 2010). 
Production of interleukin-1β is elevated by stress in healthy individuals (Ilardo, Toniolo, 
Aimone-Gastin, Abdelmouttaleb, & Desor, 2001) and increased by psychological stress 
administered in a laboratory (Heinz et al., 2003). Interleukin-1β has been proposed as a 
potential link between stress and heart disease. A study investigating this relationship 
found a positive correlation between interleukin-1β gene expression and cardiovascular 
reactivity (systolic blood pressure and heart rate) to a psychological stressor (Brydon, et 
al., 2005). Several different stress protocols have been found to cause an increase in 
interleukin-1β including speech tasks, mock job interviews and sleep deprivation 
(Ackerman, Martino, Heyman, Moyna, & Rabin, 1998; Altemus, Rao, Dhabhar, Ding, & 
Granstein, 2001; Heinz, et al., 2003). In a study comparing the stress response of 25 
patients with psoriasis and 50 healthy controls researchers found an increase in cortisol in 
both groups following the stressor; however, only the control group showed an increase 
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in interleukin-1β (Mastrolonardo, Alicino, Zefferino, Pasquini, & Picardi, 2007). 
Interestingly, the patients with psoriasis had elevated baseline levels of interleukin-1β 
perhaps suggesting a “ceiling effect” that would explain the blunted immune response to 
stress.  
The elevated levels of interleukin-1β found in obese individuals have led 
researchers to evaluate the relationship between stress and obesity. A review by Speaker 
and Fleshner (2012) describes the influence of interleukin-1β in advancing obesity 
following repeated stressors. These researchers exposed healthy, non-obese rats to a tail 
shock stressor and subsequently measured the concentration of interleukin-1β in adipose 
tissue. They found concentrations to be higher in subcutaneous compared to visceral 
adipose tissue. The researchers concluded that the inflammation in subcutaneous adipose 
tissue reduces lipogenesis and lipid uptake. This reduction in lipid accumulation by 
subcutaneous adipose tissue leads to a consequential shift in lipogenesis in visceral 
adipose tissue, thereby promoting obesity. A sustained stress response or repeated 
exposure to stress propels the detrimental shift and results in an unremitting increase in 
visceral adipose tissue. In a study of morbidly obese patients, subcutaneous expression of 
interleukin-1β decreased significantly following substantial weight loss (Moschen et al., 
2011). The effect of obesity on alterations of interleukin-1β concentration following 
laboratory stressors has not been investigated.  
Expression of interleukin-1β is one mechanism of activation for interleukin-6. 
Animal studies have shown that interleukin-6 production is increased following 
psychological and physical stressors (Zhou, Kusnecov, Shurin, DePaoli, & Rabin, 1993). 
Studies in humans have shown that experiences such as childhood maltreatment and 
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major depression are associated with increase in interleukin-6 response to acute stress 
(Carpenter et al., 2010; Pace et al., 2006). An evaluation of acute psychological stress on 
cardiovascular and immune response revealed a correlation between blood pressure 
reactivity and concentration of interleukin-6 45 minutes post task (Steptoe, Willemsen, 
Owen, Flower, & Mohamed-Ali, 2001).  
Prolonged elevation of interleukin-6 that extends beyond the termination of a 
stressor suggests impairments in immune recovery from stress. This diminished ability to 
recover from acute stress has been found in low socioeconomic populations. Thirty-eight 
participants divided into high and low socioeconomic groups showed no differences in 
baseline measures of cardiovascular and immune variables (Brydon, Edwards, Mohamed-
Ali, & Steptoe, 2004). However, the low socioeconomic group displayed a prolonged 
increase in interleukin-6 that extended temporally beyond the increase found in the high 
socioeconomic group. Further, although heart rate reactivity was the same in both groups 
blunted heart rate recovery was found in the low socioeconomic group compared to the 
high socioeconomic group.  
Like interleukin-1β, interleukin-6 is elevated in individuals with obesity 
(Roytblat, et al., 2000). The influence of obesity on the immune response to stress and its 
relationship to cardiovascular response has received some consideration. Evaluation of a 
public speaking task on obese and non-obese females revealed differences in 
cardiovascular, stress and immune measures (Benson, et al., 2009). At baseline, level of 
interleukin-6 was elevated in obese females. Acute psychological stress caused an 
increase in cardiovascular measures and interleukin-6 in both groups. The rise in cortisol 
in response to stress was elevated in the obese group; however, baseline and reactivity 
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values of cortisol were higher in the control group. The obese group also exhibited 
blunted cardiovascular and immune recovery from the stressor. At ten minutes following 
termination of the stressor diastolic blood pressure and heart rate remained elevated in the 
obese group. At 45 minutes post-stress the obese group had increased interleukin-6.  
Immunoglobulin A (IgA) has received considerably more attention in regard to 
the MA and CP stress tasks than interleukin-1β or interleukin-6. Immunoglobulin is 
another term for antibody, the protein produced by the body in response to a specific 
invader. Humans have five classes of immunoglobulins including IgA. Immunoglobulin 
A is found in the mucosal surfaces of the body as well as in tears, sweat and saliva. 
Level of salivary IgA is altered by acute stress. In response to the MA task, an 
active stressor, salivary IgA is increased (Isowa, Ohira, & Murashima, 2004; Ring et al., 
2000; Ring et al., 1999; Willemsen, Carroll, Ring, & Drayson, 2002; Willemsen et al., 
1998; Willemsen, Ring, McKeever, & Carroll, 2000; Winzer et al., 1999). Conversely, a 
passive stressor, the CP task, results in a decrease in salivary IgA (Ring et al., 2000; 
Willemsen et al., 2002). As previously mentioned the CP task is largely associated with 
cardiovascular changes resulting from α-adrenergic activation. To determine the 
relationship between immunological reactivity to the CP task and the potential influence 
of α-adrenergic activation, doxazosin, an α-adrenergic receptor antagonist, was used. 
Administration of doxazosin significantly lowered blood pressure response to the CP 
task. Further, doxazosin blocked the significant decrease in salivary IgA during the CP 
task that was seen in the placebo group (Ring et al., 2000). These results suggest α-
adrenergic and perhaps β-adrenergic pathways are responsible for some facet of both 
cardiovascular and immune response to stress. Although salivary IgA has been shown to 
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be differentially activated by stress tasks, these changes have not been investigated in 
obese individuals. 
In a study evaluating the MA and CP tasks researchers found distinctive 
influences on immune, endocrine and cardiovascular reactivity (Isowa, Ohira, & 
Murashima, 2004). The MA task increased the concentration of salivary IgA compared to 
baseline, and secretion of cortisol was significantly lower than the level during the CP 
task. Cardiovascular reactivity to the MA task did not show any relationship to salivary 
IgA or cortisol. The change in salivary IgA during the CP task was not significantly 
different from baseline, though it did show a downward trend. Cortisol increased 
significantly from baseline during the CP task and remained elevated throughout a 15 
minute rest period. A relationship did exist between cardiovascular reactivity to the CP 
task and endocrine measures. Blood pressure reactivity was negatively correlated to level 
of cortisol during the CP task. The increase in cortisol concentration to the CP task and 
the corresponding blunted blood pressure reactivity led the researchers to suggest, “the 
activity of the HPA axis might be dominant compared to that of the autonomic nervous 
system in passive stress but not in active” (Isowa et al., 2004, p. 117). The study outlined 
above was conducted on 26 female undergraduates (and one instructor) of good health 
with a mean body mass index of 21.22. The potential impact of obesity on immune 
reactivity has been largely neglected despite evidence that obesity influences the stress 
response and that the immune system can be altered by stress.  
Appraisal of the Stressor 
In 1984, Krantz and Manuck highlighted the importance of an individual’s 
appraisal of an event on cardiovascular reactivity. In instances of chronic stress, an 
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individual may be more likely to perceive a new stressor as more threatening, leading to 
increases in cardiovascular reactivity to acute stress tasks (Baum, Davidson, Rectanus, & 
McArdle, 1987). When a person is subjected to a stressful situation, the situation is 
assessed and the individual determines whether they have the resources to overcome the 
stressor. It is important to gauge the participants’ appraisal of a laboratory stressor to help 
ensure an adequate amount of stress has been evoked to elicit a response. Others have 
also acknowledged the importance of appraisal when evaluating responses to laboratory 
stress (Gump & Matthews, 1999; McEwen, 2007). It is equally important to assess an 
individual’s existing level of perceived stress. A number of variables can influence how 
an individual appraises laboratory stressors. For instance, chronic stress has been shown 
to lead to differences in acute stress appraisal (Aldwin, Sutton, Chiara, & Spiro, 1996). 
Further, animal studies have shown that repeated exposure to stress that may include 
blunted systolic reactivity could be described as a defeat response to stress (Adams, Lins, 
& Blizard, 1987). In the current study, a Likert scale of appraisal was administered to 
evaluate the feeling of stress elicited in response to the laboratory stressors. Further, the 
Perceived Stress Scale was used to assess existing levels of life stress (Cohen, Kamarck 
& Mermelstein, 1983).  
If a person decides they do not have the resources and are unable to cope with a 
stressful situation, a defeat reaction may ensue. The defeat reaction follows a different 
pattern of cardiovascular reactivity than the typical fight or flight response. Jern and 
colleagues (1992) found that participants exhibiting central obesity showed a 
vasoconstrictor response to the MA task, characterized by higher total peripheral 
resistance and decreased cardiac output. An explanation the researchers offer for this 
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finding is that obese participants respond with defeat rather than a defense reaction to this 
task. This interpretation of the data was based on hemodynamic similarities to rats 
exposed to mental stress defined as immobilization stress (Hallbäck, Magnusson, & 
Weiss, 1974). Performance during the MA task was not reported, thus it is unknown 
whether the defeat pattern of cardiovascular reactivity corresponds to a behavioral 
manifestation of defeat represented by lack of effort during the task (Jern, Bergbrant, 
Björntorp, & Hansson, 1992).  
A study by Carroll and colleagues (2008) did evaluate performance on the MA 
task. They found performance to be positively correlated with reactivity (systolic blood 
pressure and heart rate). Further, obesity was associated with poorer performance on the 
task. Blunted reactivity in obese participants during the MA task may be a consequence 
of a decreased ability to cope. The resulting defeat pattern of response may include both 
blunted cardiovascular reactivity and poor performance on the task. In an attempt to 
assess performance during the MA task in the current study, responses were recorded and 
subsequently coded. If a participant gives up or quits responding, this may suggest a 
defeat response. Participants were also asked to rate how hard they tried to successfully 
complete the task and whether or not they felt like they gave up during the task.  
Assessment of pain during the CP task was also evaluated by having participants 
rate their experience of pain. It should come as no surprise that obesity is associated with 
a diminished health-related quality of life. Interestingly, pain appears to moderate the 
relationship between obesity and health-related quality of life (Barofsky, Fontaine, & 
Cheskin, 1997; Heo, Allison, Faith, Zhu, & Fontaine, 2003). Studies have shown that 
pain sensitivity may be elevated in obese individuals. Different techniques have been 
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used to assess pain sensitivity; obese participants have reported amplified pain to a 
pressuring bearing device and electrophysiological methods (McKendall, & Haier, 1983; 
Zahorska-Markiewicz, Zych, & Kucio, 1988). The experience of pain is also related to 
cardiovascular reactivity, with greater reactivity being associated with increased ratings 
of pain (Peckerman et al., 1991). An interesting study by Caceres and Burns (1997) found 
that pain sensitivity could be enhanced by prior exposure to psychological stress. These 
researchers divided participants into two groups (high and low responders) based on 
blood pressure reactivity to the MA task. Participants then completed the CP task. High 
responders to the MA task exhibited a lower pain threshold and tolerance to the CP task. 
Not all studies have confirmed the relationship between enhanced pain sensitivity 
and obesity. Some findings suggest obese rats are less sensitive to pain. The tail flick test 
is a commonly used task in the evaluation of pain perception in rats. In this thermal-pain 
detection task, a beam of light is concentrated on the rat’s tail, the amount of time it takes 
for the rat to move their tail away from the light (heat) is a measure of pain threshold. 
Ramzan, Wong and Corcoran (1993), found that obese rats exhibited a decrease in pain 
avoidance behavior measured by an increase in tail flick latency. Moreover, weight of the 
rat was positively correlated to latency. Thus, the more the rat weighed the longer it took 
to move its tail away from the heat. The differences that have been found in the 
relationship between pain sensitivity and obesity indicate the importance of assessing 
pain perception in the current study. Further, controlling for the perception of pain may 
be important when evaluating cardiovascular reactivity given the potential relationship 
between pain and reactivity. 
Gender 
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The existence of individual differences are known with respect to cardiovascular 
reactivity and recovery; however, there may be a gender component that adds to these 
differences. Thus, gender differences can complicate findings. For example, it has been 
demonstrated that women tend to have greater cardiovascular reactivity to some 
laboratory stressors than men (Matthews, 2004; Schmaus, Laubmeier, Boquiren, Herzer 
& Zakowski, 2008). Others have shown that women but not men have a blunted response 
to some laboratory stressors (Dishman & Nakamura, 2003). A gender dimorphism in 
cardiovascular response may also result in differences with females exhibiting a 
“cardiac” response and males a more “vascular” response to stress (Allen, Stoney, 
Owens, & Matthews, 1993).  
In addition to the relationship between cardiovascular reactivity and perception of 
pain described previously, gender may also have an effect on pain ratings. Extensive 
literature reviews report that women have greater pain sensitivity, thus a lower pain 
threshold than men (Fillingim, King, Ribeiro-Dasilva, Rahim-Williams, & Riley III, 
2009), though some suggest that this gender disparity may be task specific (Racine et al., 
2012). In response to the CP task, researchers have found that women are significantly 
less tolerant of pain compared to men (Hellström, & Lundberg, 2000; Keogh, Bond, 
Hanmer, & Tilston, 2005).  
Alterations in immune measures have also been found between men and women. 
Some researchers have found increases in salivary IgA following the MA task in men, 
but not in women (Willemsen et al., 2002). Numerous studies have found gender 
differences in stress appraisal and coping; however, these differences have not been 
consistent (for a review see, Davis, Matthews, & Twamley, 1999; Jick, & Mitz, 1986). 
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The causes for these discrepancies are not well understood. The limited sample size of 
the current study will not allow us to evaluate any possible effects of gender. 
Additionally, due to the limited amount of research that has been conducted in obese 
populations investigating the relationship between stress and cardiovascular and immune 
changes this study will be largely exploratory. For these reasons only females were 
recruited for the current study.  
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II. PROPOSED RESEARCH 
As the obesity epidemic increases, the prevalence of obesity-related diseases 
grows simultaneously. Obesity characterizes an internal environment of low-grade 
chronic inflammation, which exacerbates cardiovascular dysfunction. A large body of 
research substantiates the pathophysiology linking obesity and cardiovascular 
dysfunction (Alpert, 2001; Cassidy, et al., 2005; Freedman, et al., 2004; Kenchaiah, et al., 
2002). Unfortunately, immunoregulatory dysfunction has yet to receive the same 
attention in obese populations. However, it has been hypothesized that similar 
mechanisms are responsible for cardiovascular and immune response to stress.  
Previous studies have shown that different stress tasks can activate different 
patterns of stress response. Two common tasks that are used are the MA and the CP task. 
Our lab has successfully demonstrated the ability of these stress tasks to elicit distinct 
patterns of cardiovascular stress response in obese, young adult females (Burch & Allen, 
in press). Participants with a higher body mass index showed greater diastolic blood 
pressure response to the CP task. In contrast, systolic blood pressure and heart rate 
response to the MA task was blunted in participants with a higher body mass index. 
In the current study, we have expanded recruitment to a more diverse population 
of adult females, thus adding to the population to which our findings are relevant. In 
addition to validating earlier results from our lab and expanding their relevance, the 
present study allowed us to investigate obesity-instigated alterations in immune response 
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to different stressors (active versus passive). This was done by investigating 
cytokines that act as signalers of the innate immune response. We also measured changes 
in the adaptive immune response to stress by evaluating levels of salivary IgA.  
We believe obese individuals will have a different immune response to laboratory 
stress compared to normal weight individuals. Many studies have shown that 
inflammatory cytokines, interleukin-1β and interleukin-6, are elevated in obese 
individuals. The potential influence this has on the acute stress response remains largely 
unknown. Some researchers have suggested that elevated cytokine levels at baseline may 
have a limiting effect on the increase that could occur in response to stress. Researchers 
have also found correlations between cardiovascular response to a stressor and change in 
cytokine concentration. This indicates there may be some link between sympathetic 
nervous system activation and immune response to stress. However, increases found in 
cortisol concentration during the CP task coupled with blunted blood pressure reactivity 
led researchers to propose that the stress response may be dominated by the HPA axis 
following passive stress.  
This distinction in response to active and passive stressors is what we aim to 
investigate in obese individuals. Specifically, we plan to examine reactivity and recovery 
in the cardiovascular, immune and endocrine systems. Finding a way to stop or 
drastically reduce the obesity epidemic would be the paramount answer to the negative 
implication of excess adipose tissue on the cardiovascular and immune systems. Obesity 
has been on the rise for years and shows no signs of slowing. For this reason it is 
imperative that research efforts be made to understand the implications of obesity on vital 
body systems. The cardiovascular and immune systems are arguably two of the most 
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critical. Understanding how these systems are affected will lead to immediate but short-
term solutions buying much needed time for the larger issue of obesity to be resolved.  
Our hypothesis is that individual levels of obesity alter the cardiovascular, 
immune and endocrine stress response. These alterations are differentially based on the 
type of stress (e.g. passive vs. active). More specifically, we hypothesize that obese 
individuals will have a greater sympathetic and endocrine response to passive stress, as 
measured by cardiovascular variables, alpha-amylase and cortisol. Conversely, following 
active stress the sympathetic and endocrine response is blunted in obese individuals.  
Finally, although both obese and non-obese individuals exhibit an elevated immune 
response to active compared to passive stress as measured by interleukin-6 and IgA. 
However, this increase in response to active stress is blunted in obese participants.  
Specific Aims 
Specific Aim 1: Confirm previous cardiovascular findings from our lab, which show that 
obese females are more reactive to passive stress, yet exhibit blunted reactivity to active 
stress. Further, we expect greater adiposity will result in delayed recovery following both 
stress tasks.  
Specific Aim 2: Evaluate obesity-related HPA axis reactivity and recovery from 
stressors.  
Specific Aim 3: Investigate obesity-instigated alterations in interleukin-1β and 
interleukin-6 during reactivity and recovery from different types of stressors (passive and 
active). 
Specific Aim 4: Explore the relationship between obesity and salivary IgA alterations to 
different stressors. 
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Specific Aim 5: Evaluate overlap between dysfunctional endocrine, immune and 
cardiovascular response to passive and active stress. 
Aim 1: will be achieved by measuring cardiovascular activity (blood pressure and 
heart rate) before, during and following completion of the two stress tasks. 
Cardiovascular data will be compared to the results from our previous study, a population 
of obese and non-obese college-age females. We expect to find similar patterns of 
cardiovascular reactivity that will be dependent on weight as well as task type. 
Cardiovascular data is often used as a measure of sympathetic nervous system activation 
in response to stress. We are also interested in the influence of obesity on the HPA axis, 
which often acts in concert to promote the stress response.  
Aim 2: will be completed by measuring levels of cortisol, the main effector of the 
stress response initiated by the HPA axis, at set time points throughout the study.  
Obesity has been shown to have an adverse impact on immunoregulatory 
networks, which results in compromised immunity (Pallaro, et al., 2002). However, what 
is lacking in this body of literature is the impact of obesity on immune response to 
variable types of stress. Past research, evaluating the effects of obesity on the immune 
response to stress has focused almost exclusively on psychological stress with tasks 
similar to MA. Thus, researchers have failed to take advantage of the differences in stress 
response that task type may elicit. The present study proposes to investigate the immune 
response in obese participants in a novel context by utilizing the MA and CP stress tasks 
to uncover variations in immune reactivity based on task. Interleukin-1β and interleukin-
6 may be involved in the inflammatory process that link obesity and vascular dysfunction 
(Calabro et al., 2005). In a comprehensive review Steptoe, Hamer and Chida  (2007) 
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assessed the influence of acute psychological stress on circulating cytokines. The review, 
which included thirty studies, found robust effects for the influence of stress on elevating 
levels of interleukin-1β and interleukin-6. 
Aim 3: will be addressed by investigating alterations in of interleukin-1β and 
interleukin-6 in saliva. Recent studies show that obesity may mediate the effect of stress 
on immune response. Obesity is positively correlated to elevated levels of interleukin-1β 
and interleukin-6. We predict obese participants will have elevated concentrations of 
interleukin-1β and interleukin-6. Further, we expect fluctuations in these cytokines to be 
differentially influenced by type of stressor.  
Salivary IgA is a more thoroughly studied measure of immune response to acute 
stress. However, the lack of investigation using this measure represents another void that 
exists in evaluating the effect of passive stress on immune reactivity in obese participants. 
Aim 4: will be achieved by quantifying baseline levels of salivary IgA and 
calculating change and recovery scores following the stress tasks.  
Willemsen and colleagues (2002) measured immune changes in healthy, normal-
weight participants. They found a decrease in immune measures following the CP task 
and an increase following the MA task. Moreover, α-adrenergic blockade has been 
shown to inhibit the decreases following the CP task (Ring, et al., 2000). This result 
suggests α-adrenergic activation is likely involved in the immune response to the CP 
task. Thus, the adrenergic pathways may be responsible for some facet of both 
cardiovascular and immune response to stress. Further, increases in immune response to 
stress that coincide with blood pressure reactivity suggests alterations in immune 
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measures following stress may correspond to sympathetic activation, as indicated by 
blood pressure reactivity (Steptoe et al., 2001).  
Aim 5: will be evaluated by comparing the cardiovascular, HPA axis and immune 
response for each stressor. Based on previous research suggesting a link between 
sympathetic and HPA axis activation by stress we expect cortisol to follow a similar 
pattern of reactivity in obese participants. Specifically, in response to passive stress we 
expect a greater increase in cortisol in obese participants compared to non-obese, while 
active stress in obese participants will result in blunted levels of cortisol. Cardiovascular 
and immune dysfunction is often seen in conjunction with obesity (Ritchie, & Connell, 
2007; Martin, Qasim, & Reilly, 2008; Singer, & Granger, 2007).  
Elevations of interleukin-1β and interleukin-6 commonly found in obese 
individuals may have some effect on reactivity concentrations of these measures. The 
sensitivity of interleukin-1β and interleukin-6 to acute stress makes them ideal targets for 
evaluating immunoregulatory dysfunction, allowing us to explore our final aim.  
Innovation and Significance  
Although the foundation exists for the study of immune dysfunction in obese 
individuals, many avenues have yet to be explored. This study will be the first to examine 
the effects of obesity on immune and cardiovascular response to passive and active stress. 
The interdisciplinary nature of this study permits findings that may be of relevance to the 
disciplines of cardiovascular psychophysiology and psychoneuroimmunology among 
others. Our preliminary study demonstrated that obesity influences cardiovascular 
reactivity to stress that is conditionally based on type of stress.  
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The current study seeks to further establish the relationship between obesity and 
cardiovascular dysfunction and investigate the role of obesity in immune dysfunction. 
The current body of immune research has overlooked the importance of differential 
activation based on task type in obese individuals. This will be the first study to examine 
immunoregulatory alterations in obese individuals following passive as well as active 
stress. 
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III. METHODS 
Participants 
Forty-four females were recruited from Oxford, MS and the surrounding area. 
Participants were recruited through flyers posted in hospitals, clinics and other venues; 
print media (e.g., local newspaper); and through electronic recruitment (e.g., Facebook, 
craigslist, University mailing lists, etc.).  
Mean age was 22.3 (SD = 5.9). All participants were non-smokers, with no 
infectious illness or history of cardiovascular dysfunction or currently taking medication 
for hypertension or steroids (as self-reported). Participants were classified as obese or 
non-obese based on the BMI; four participants had BMIs that fell outside of the group 
ranges and were excluded from analyses. The mean BMI of the obese group was 41.9 
kg/m2 (SD = 7.2). For the non-obese group the mean body mass index was 22.3 kg/m2 
(SD = 1.6). 
Measures 
Anthropometric measures. 
Body mass index. – BMI was calculated for each participant by the experimenter 
using the standard formula of body weight in kilograms divided by the square of height 
measured in meters. Weight was measured using a manual balance beam scale in pounds 
then converted to kilograms. Height was measured using a mechanical stadiometer in 
inches then converted to meters. 
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Waist circumference. – Waist circumference was obtained using measuring tape 
placed horizontally across the abdomen approximately at the navel. In participants where 
the rib cage could be seen or palpated without discomfort, the tape was specifically 
placed horizontally between the twelfth rib and the ileac crest. Waist circumference was 
recorded in inches. 
Waist to hip ratio. – Each participant’s measurement obtained from the waist 
circumference was divided by the hip circumference in order to calculate the waist to hip 
ratio. Hip circumference was obtained using measuring tape placed horizontally around 
the body at the widest point of the gluteus maximus. The hip ratio was recorded in inches.  
Physiological measures. 
Blood pressure and heart rate. – A Suntech Tango automated blood pressure 
monitor was used to measure systolic and diastolic blood pressure. A blood pressure cuff 
was placed on the non-dominant upper arm of the participant. During cuff inflation, heart 
rate was also recorded.  
Heart rate variability. - Electrocardiographic data were collected using a Biopac 
MP150 system (Biopac Systems Inc., CA, USA), with accompanying amplifier. The 
electrocardiogram (ECG) activity was sampled at 1000 Hz and filtered in real-time using 
a band pass (low = 0.5 Hz, high = 35 Hz) filter. This allowed high frequency noise and 
baseline drift to be removed from the signal. AcqKnowledge (Biopac Systems Inc., CA, 
USA) data acquisition software was used to display the ECG on a computer screen. This 
allowed viewing in real-time; in addition, a copy was stored on a Dell personal computer 
for later analysis. Heart rate variability was calculated for baseline, tasks and recovery 
periods. 
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A three-electrode setup was used for HRV data acquisition; disposable 
silver/silver chloride electrodes were used. Lead II electrode placement was as follows: 
negative electrode was placed right below the clavicle in the intercostal space along the 
right midclavicular line, ground electrode was placed right below the clavicle in the 
intercostal space along the left midclavicular line, positive electrode was placed on the 
left abdomen, just under the breast.  
An event detector was used to detect R-wave peaks. The threshold for events was 
set manually following a visual inspection of the data. The peak was defined as the 
maximum value obtained within a narrow window of time. The start of this window of 
time was demarcated by an upward crossing of the threshold (i.e., while the slope was 
positive) and the end of this period of time was demarcated by a downward crossing of 
the threshold. Once all the R-waves had been detected, a visual inspection was performed 
and manual corrections were carried out to exclude abnormal beats and identify artifacts. 
Time domain analysis was chosen to assess HRV. Markers placed at the peak of 
the R waves were used to extract the time at which the beat occurred and to calculate the 
time periods between adjacent R-waves (R-R interval). Both the time data and the 
corresponding R-R intervals were exported to excel. The data were divided into segments 
and HRV was calculated for each segment.  
The mean successive difference statistic was computed for baseline, tasks and 
recovery periods; these values are reported in milliseconds (ms). This method has been 
used in a number of studies (Allen, Matthews, & Kenyon, 2000; Christie & Friedman, 
2004). This statistic represents the average of the difference between successive 
heartbeats for a given period of time and is used as a measure of heart rate variability. As 
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a differencing technique, the measure removes slow changes due to drift in the R-R 
interval series (Weinberg & Pfeifer, 1984), and it has accurately tracked both 
pharmacologically manipulated changes in cardiac vagal control (Hayano et al., 1991) 
and changes in vagal activation with passive head-up tilt (Vybiral, Bryg, Maddens, & 
Boden, 1989). Indeed, Hayano and colleagues (1991) found that the mean successive 
difference showed the highest correlation (r = 0.92) among eleven other potential HRV 
measures with change in mean R-R interval as a result of complete vagal blockade with 
atropine and sympathetic blockade with propranolol. 
Endocrine and Immune measures. 
Cortisol, Interleukin-6, Immunoglobulin A and Alpha-amylase. – Salivary 
samples were collected using the passive drool technique. The collection date, start time 
and time completed were recorded. Flow rates were calculated and recorded as part of the 
conversion factor needed for the final concentration analysis.  
Saliva was collected from participants at 7 different time points; approximately 
two milliliters of saliva was collected at each time point. Immediately following 
collection, samples were stored in a cooler on ice. At the end of the study session 
(approximately 2.5 hours) samples were transferred to a freezer set to -80 degrees Celsius 
for storage. Once all saliva samples were collected, they were transported to Jackson, MS 
to the lab of Dr. Gailen Marshall for analysis. Samples were transported on ice and 
remained frozen for the duration of the trip.  
Once at the lab, all samples were thawed and weighed. Sample preparation for 
analysis began by centrifuging samples at 1500 g (@3000 rpm) for 15 minutes. This 
allowed mucins and other particulates to be removed from the sample, which may 
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otherwise disrupt antibody binding. The supernatant was then aliquoted into separate 
microcentrifuge tubes (~500 ul) to be used in separate assays and stored at -20 degrees 
Celsius. On the day the assay was to be performed, the appropriate samples were 
removed from the freezer, thawed and vortexed.    
It was our desire to measure interleukin-1β, due to its role in obesity related 
inflammation. However, in consideration of its partial overlap with interleukin-6 it was 
decided that only interleukin-6 would be measured at this time. In addition, the 
assessment of alpha-amylase was added. This salivary analyte demonstrates a close 
relationship to catecholamines, which typically require a blood sample for analysis; 
further, alpha-amylase has been shown to be a sensitive measure of sympathetic 
activation (Thoma, Kirschbaum, Wolf & Rohleder, 2012; van Stegeren, Rohleder, 
Everaerd, & Wolf, 2006). 
Saliva samples were analyzed using commercially available assay kits 
(Salmetrics, State College, PA). Cortisol, interleukin-6 and IgA were analyzed using 
enzyme-linked immunosorbent assay (ELISA). Alpha-amylase was analyzed using a 
kinetic reaction assay kit. Manufacturer supplied protocols were followed for all salivary 
assays. All samples were assayed in duplicate and mean scores were used in statistical 
analysis.  
Questionnaires. 
Perceived stress scale – 10 (PSS). – The PSS-10 consists of 10 items with 
responses on a five-point Likert scale. The PSS is a self-report measure used to obtain 
how stressful participants perceive events in their life to be. The PSS has demonstrated 
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reliability with an alpha coefficient ranging from .84 to .86 depending on the sample 
population (Cohen, Kamarck, & Mermelstein, 1983).  
Brief COPE. – The brief COPE consists of 28 items with responses on a four-
point Likert-type scale. The Brief COPE is an abbreviated version of the COPE. This 
self-report measure is designed to measure coping strategies based on 14 subscales: self-
distraction, active coping, denial, substance use, use of emotional support, use of 
instrumental support, behavioral disengagement, venting, positive reframing, planning, 
humor, acceptance, religion and self-blame. Reliability analysis performed on repeated 
administrations of the subscales has produced alpha coefficients averaging at or above 
.50 (Carver, 1997). 
Likert scale of perceived stress specifically from laboratory stressors. – A 10 
point Likert-type scale ranging from 0 (Not Stressful) to 9 (Extremely Stressful) was 
given to participants to assess the self-reported stress produced by each laboratory 
stressor administered. During the CP task (minutes 1 and 4) participants were asked to 
rate their experience of pain from 0 (Not Painful) to 9 (Extremely Painful). Immediately 
following the conclusion of the CP task they were asked to give a final pain rating. 
Following the MA task participants were asked to rate how hard they tried to successfully 
complete the task 0 (Not Hard) to 9 (Extremely Hard) and whether or not they felt like 
they gave up during the task. 
Laboratory Stressors 
Cold pressor. 
The CP task lasted for a total of 8 minutes. Participants were asked to place their 
right hand in a container filled with ice and water. The participant was instructed to place 
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their hand palm down, with fingers spread apart to allow adequate water coverage, in the 
container. Using the pisiform bone as a landmark, the participant was asked to keep the 
water at a horizontal level across the wrist just above this bone. Water temperature was 
maintained near 10 degrees Celsius; a pump was used to circulate water from a chamber 
containing ice and water into the chamber with the participant’s hand. Water temperature 
was measured using a digital thermometer just prior to the task and temperature was 
recorded on the data sheet. 
Mental arithmetic. 
The MA task lasted for a total of 8 minutes during which the participant was 
asked to subtract verbally by 7s from 921 as quickly and accurately as possible. Answers 
were monitored and if the participant gave an incorrect answer, the experimenter 
corrected the participant, and then asked them to continue from the last correct response. 
The MA task was audio recorded and subsequently coded for number of answers 
attempted and number of correct answers. 
Procedure 
A waiver of signed consent was requested from the Institutional Review Board in 
order to obtain screening information from potential participants. Participants’ age, 
history of smoking, current illness, history of cardiovascular dysfunction and current 
medications (hypertension, depression, steroids or beta-blockers) was used to assess 
inclusion and exclusion criteria. Further, self-reported weight and height was used to 
screen potential participants. 
Prior to the study visit, potential participants were given written instructions 
asking that they: do not consume alcohol or caffeine or exercising vigorously for at least 
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12 hours before the study session; they should eat a light breakfast at least 1 hour before 
their session; be aware of their dental hygiene, on the night before the session be careful 
not to make their gums bleed, and do not brush their teeth on the morning of the session. 
Participants were contacted the night before the study session to remind them of the 
restrictions. To control for the circadian rhythm of cortisol and cardiovascular activity, all 
study visits were scheduled in the morning, beginning between 8:30am - 9am and 
concluding no later than 11:30am. 
Upon entering the laboratory the participant was invited to sit in a lounge chair, 
all potential participants were given an informed consent form to read over and sign. 
After the consent form was signed, the participant was assigned an identification number 
and asked a series of questions to collect demographic information and determine any 
contraindications to participation in the study (e.g., age, cardiovascular risk factors, oral 
contraceptive use, adherence to pre-session instructions). The participant was then asked 
to complete two questionnaires, the PSS and the Brief COPE. Next, the passive drool 
method of saliva collection was explained to the participant. 
The participant was instructed to turn off or silence their cell phone. A blood 
pressure cuff was placed on the left upper arm. Following a brief explanation of electrode 
placement electrodes were placed on the participant. A three-leadwire system was used. 
Immediately prior to placing the electrodes, the area was cleansed with an alcohol wipe. 
The wipe was also used to gently abrade the area to encourage conductivity of electrical 
signal. The participant was then instructed to rest quietly while reading through a 
selection of magazines for ten minutes. The magazines were used to encourage relaxation 
while giving participants some stimuli to prevent sleeping. Magazines were screened for 
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distressing or offensive content. During this initial rest period heart rate was measured 
continuously for the ten minutes. A baseline value of heart rate variability was calculated 
by averaging the mean successive difference at minute two through just before minute 
four, and minute four through just before minute six. These two mean successive 
difference values were then averaged for a baseline value of heart rate variability.  
Blood pressure and heart rate were taken at the beginning of the first, third, fifth, 
seventh and ninth minute during the baseline rest period. The first reading was used to 
acclimate the participant to the feeling of the blood pressure cuff inflating and give the 
participant time to relax. Thus, this reading was discarded. The second and third readings 
were averaged and the single number was used as the baseline blood pressure and heart 
rate reading. The fourth and fifth readings were also discarded due to elevations during 
saliva collection. The first saliva collection occurred at minute seven of the baseline rest 
period. The collection start time and completion time were recorded on the data sheet. 
Once the initial rest period was complete, the participant performed either the MA 
task or the CP task; the order was counterbalanced. The MA task lasted for a total of 
eight minutes. Performance of the MA task was recorded for later evaluation. During the 
MA task, blood pressure and heart rate readings were recorded at minutes zero, one, 
three, five and seven. The first three measurements were averaged to determine a mean 
blood pressure and heart rate score for the task.  
Heart rate was recorded throughout the task. A mean heart rate variability score 
was calculated for each task by averaging the mean successive difference at minute zero 
through just before minute two, and minute two through just before minute four. These 
two mean successive difference values were then averaged for a task value of heart rate 
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variability. A saliva sample was taken immediately following the task. Following the MA 
task the participant was given the MA Stress Questionnaire, where they rated their 
perception of the degree of stress produced by the MA task, their perceived effort and 
whether or not they gave up during the task. 
The CP task lasted for a total of eight minutes. During the CP task, blood pressure 
and heart rate readings were recorded at minutes zero, one, three, five and seven. The 
first three measurements were averaged to determine a mean blood pressure and heart 
rate score for the task. A saliva sample was taken immediately following the task. 
Following the CP task the participant was given the CP Stress Questionnaire, where they 
rated their perception of the degree of stress produced by the CP task and the amount of 
pain experienced during the task. Following the first task, be it the MA task or the CP 
task, the participant was asked to sit quietly and read the magazines provided for a second 
rest period that lasted for forty minutes. Heart rate variability was recorded continuously 
until minute twelve of the rest period. Blood pressure and heart rate readings were taken 
at the beginning of minutes: one, three, five, seven, nine, twelve, fifteen, twenty, twenty-
five, thirty, thirty-five and forty. Saliva samples were taken at minute 20 and minute 40. 
Subsequent to administration of the final laboratory stressor, the participant had a third 
and final rest period. During this time blood pressure, heart rate, heart rate variability and 
saliva was taken as described for the second rest period. The blood pressure cuff and 
electrodes were then removed. 
Next, weight and height was measured. In the interest of protecting female 
participants’ privacy only female experimenters were in the room at this time. The 
participant was asked to remove their shoes and any outerwear that could affect their 
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weight. Waist circumference was measured using the method described above. The 
participant was asked to raise their shirt to their belly button to ensure accurate 
measurement. The participant was instructed to stand up straight and breathe normally 
being sure not to hold their breath. The hip circumference measurement was then taken 
using the method described above. The participant was debriefed and any questions they 
had regarding the study was answered. 
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IV. RESULTS 
Anthropometric measures 
Independent groups t-tests were performed in order to verify differences between 
BMI groups on anthropometric measures. All statistical analyses were performed using 
SPSS with a type I error level set at p = 0.05, unless otherwise noted. Between-group 
differences were evaluated for BMI, WC (measured in inches), WHR and weight 
(measured in pounds). As expected, there were significant group differences with the 
obese group having significantly higher WC (obese mean = 46.7, SD = 6.5; non-obese 
mean = 31.8, SD = 2.4; t(38) = -9.61, p < 0.000), WHR (obese mean = 0.9, SD = 0.1, 
non-obese mean = 0.8, SD = 0.05, t(38) = -3.95, p = 0.001) and weight (obese mean = 
255.2, SD = 54.5, non-obese mean = 133.3, SD = 11.3, t(38) = -9.80, p < 0.000) (Table 
1).  
Analysis of questionnaires 
To evaluate group differences in questionnaire scores a series of t-tests were 
performed. Table 2 presents the means and standard deviations for the obese and non-
obese groups on PSS, stress experienced during the CP and MA tasks, pain experienced 
during minute one and minute four of the CP task and perceived effort during the MA 
task. PSS scores were within the normal range for both groups, scores of 20 or higher are 
typically seen in high stress populations. There were no significant differences between 
the obese and non-obese group on any of the questionnaire scores.  
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The Brief COPE was administered to uncover differences in coping styles 
between the two groups. Of the 14 subscales on the Brief COPE, there were two that 
showed significant group differences, denial and behavioral disengagement. Questions 
used to assess denial included: “I've been saying to myself "this isn't real” and “I've been 
refusing to believe that it has happened.” Behavioral disengagement was appraised using 
the following statements: “I've been giving up trying to deal with it” and “I've been 
giving up the attempt to cope.”  
Due to violations of Levene’s test, showing an unequal distribution of variance 
between the groups, adjustments were made to p-values. Even after adjustment, the obese 
group showed greater use of denial (obese mean = 3.1, SD = 1.7, non-obese mean = 2.1, 
SD = 0.3, t(38) = -2.57, p = 0.018) and behavioral disengagement (obese mean = 3.3, SD 
= 1.5, non-obese mean = 2.5, SD = 0.9, t(38) = -2.07, p = 0.047) than the non-obese 
group. 
Mental arithmetic performance 
Participants’ responses during the MA task were recorded for later analysis. 
Following the study session the recordings were coded for number of responses 
attempted and number of incorrect responses. These values were used to calculate 
number of correct responses as well as an overall percent correct. The means and 
standard deviations for the obese and non-obese groups on total number of responses 
attempted and percent of correct responses are presented in Table 3.  
Performance on the MA task was evaluated between groups. There were no 
significant differences between the two groups on number of responses attempted (p = 
0.335) or percent of correct responses (p = 0.450). 
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Group differences in baseline levels of cardiovascular and salivary measures 
In order to determine group differences present at baseline, t-tests were used to 
compare baseline levels of all cardiovascular (SPB, DBP, HR and HRV) and salivary 
(cortisol, interleukin-6, IgA and alpha-amylase) measures. As expected, the obese group 
had significantly higher SBP, DBP and HR levels at baseline, although all values were 
within an acceptable clinical range. Baseline level of HRV was not significantly different 
between groups; however, the obese group did have a trend towards a lower level of 
HRV as would be expected (Table 4). 
Salivary data were incomplete for a subset of the measures. To analyze saliva, 
manufacturer recommended dilutions were used when assaying the samples. This 
resulted in an over dilution of a portion of the samples and thus there were insufficient 
analytes present for detection. Sample size for each of the salivary measures is presented 
in Table 5. Inspection of the salivary measures revealed subsets that were not normally 
distributed. Based on outcomes from visual inspection of the data and the Shapiro-Wilk 
test (used due to sample size less than 50) for normality, IgA and alpha-amylase were 
found not to be normally distributed. To approximate a normal distribution a base 10 
logarithmic transformation was used for analysis of baseline difference and all other 
analysis of IgA and alpha-amylase. 
Analysis of group difference between baseline level of salivary measures revealed 
significant differences in levels of cortisol and alpha-amylase, t(37) = 2.87, p = 0.007 and 
t(38) = 2.29, p = 0.027, respectively. The obese group had lower levels of both cortisol 
and alpha-amylase at baseline. There were no significant group differences found in 
baseline levels of interleukin-6 or IgA (Table 6).  
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Cardiovascular manipulation check 
Prior to evaluating difference in cardiovascular reactivity, we first wanted to 
establish that significant differences were present between baseline levels and task levels 
on the cardiovascular measures; that is, that our tasks did indeed produce significant 
levels of cardiovascular response compared to baseline. Each physiological variable was 
analyzed individually utilizing a two-factor (2 group x 3 periods) repeated measures 
analysis of variance (ANOVA). The grouping factor was used to separate participants 
into the obese and non-obese groups; analyses were then performed to compare baseline, 
CP, and MA levels of SBP, DBP, HR and HRV (Figure 1). Greenhouse-Geisser 
corrections were used for two of the ANOVAs (DBP and HR) due to violations of 
sphericity. There were no significant interactions between period and group. There was a 
significant main effect of period for all cardiovascular variables with the exception of 
HRV: SBP (F(2, 76) = 34.179, p < 0.000), DBP (F(1.681, 76) = 42.263, p < 0.000) and 
HR (F(1.623, 76) = 5.912, p = 0.007).  
Follow up pairwise comparisons were evaluated to confirm both stressors (CP and 
MA) produced effects that were significantly different from baseline for cardiovascular 
measures (SBP, DBP and HR) averaging across both groups. Adjustments to alpha levels 
for multiple comparisons were done using Bonferroni corrections. For SBP, the level 
during the CP (mean = 130) and MA (mean = 128) task were significantly higher than the 
level at baseline (mean = 119, both ps < 0.000). Level of DBP during the CP (mean = 82) 
and MA (mean = 80) tasks were also significantly higher than at baseline (mean = 72, 
both ps < 0.000). For HR, both tasks (CP, mean = 80, p = 0.020 and MA, mean = 82, p = 
0.007) showed elevated levels compared to baseline (mean = 78). Although the analysis 
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of HRV was not significant, the data showed a non-responsive trend by the obese group 
across periods (baseline mean = 29.5, CP mean = 29.1, MA mean = 29.3) in comparison 
to the non-obese group (baseline mean = 37, CP mean = 38.4, MA mean = 30.2). 
There was also a significant main effect of group (obese and non-obese) for SBP 
(F(1,38) = 25.390, p < 0.000) and DBP (F(1, 38) = 13.023, p = 0.001). No other main 
effects were present. Follow up pairwise comparisons revealed that the obese group had 
higher levels of SBP (obese = 133, non-obese = 119, p < 0.000) and DBP (obese = 81, 
non-obese = 75, p = 0.001) when averaged across the three periods.  
Based on these findings, we conclude that our stress tasks did produce a 
significantly elevated cardiovascular (SBP, DBP and HR) response; further, although not 
significant, there was a different pattern of HRV response to the stress tasks between 
groups. In addition, the elevated levels of basal blood pressure present in the obese group 
did not hinder their reactivity to the stress tasks, demonstrated by the significant main 
effect of group across all three periods.  
Analysis of cardiovascular reactivity 
Aim one was divided into two parts; the first part was to evaluate cardiovascular 
reactivity differences between groups to the two stress tasks. This was achieved by 
utilizing a mixed-model, repeated measures analysis of covariance (ANCOVA). In these 
(2 group x 2 period) ANCOVAs, group (obese and non-obese) was used as a between-
subjects factor and differences between reactivity values (calculated as the difference 
between task average and baseline) for the CP and MA task were the within-subjects 
factor; baseline values were entered as a covariate.   
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There was no significant interaction for SBP. However, there was a significant 
main effect of group (F(1, 37) = 5.775, p = 0.021) (Table 7). The average SBP reactivity 
value across both tasks was 12.5 for the obese group and 6.8 for the non-obese. For DBP, 
the interaction was also not significant; but again a main effect of group was present 
(F(1,37) = 9.308, p = 0.004). The average DBP reactivity value was 11.3 for the obese 
and 6.6 for the non-obese. There was a significant interaction between group and task for 
HRV (F(1,37) = 4.381, p = 0.043). Follow up analysis did not reveal any significant 
differences between groups for either task (CP, t(38) = 0.427, p = 0.672; MA, t(38) = -
1.389, p = 0.173).  
Figure 2 displays change scores for each of the cardiovascular variables separated 
by group. On average, the obese group experienced greater blood pressure reactivity in 
response to stress. Based on visual inspection of Figure 2, the exaggerated reactivity 
appears to be similar across tasks for DBP; however, for SBP reactivity the obese group 
appears to have greater reactivity to the CP task. HRV reactivity is illustrated in Figure 
2d, the obese group appears to have a similar level of HRV across the two stress task. In 
contrast, the non-obese group shows greater HRV during the CP task in comparison to 
level during the MA task. There were no significant main effects, period effects or 
interactions for HR during the tasks.  
Analysis of cardiovascular recovery 
The second part of aim one was to evaluate cardiovascular recovery differences 
between groups following termination of the two stress tasks. Recovery was investigated 
for each physiological measure using a (2 group x 3 period) mixed-model, repeated 
measures ANCOVA. Recovery was divided into early, middle and late recovery. For 
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blood pressure and HR, early recovery was calculated as the difference between task 
average, and an average of minutes one and three of the recovery period (see Figure 3). 
Likewise, middle recovery was calculated as the difference between task average, and an 
average of minutes five and seven of the recovery period, and late recovery as the 
difference between task average, and an average of minutes nine and twelve of the 
recovery period. For HRV, recovery was also divided into early, middle and late periods. 
Due to the continuous measurement of this variable the twelve minutes of recorded HRV 
were divided into six even segments and mean successive difference scores were 
computed for each of the six segments. The six scores were then divided into three pairs; 
the pairs were then averaged to form early, middle and late periods (see Figure 4). HRV 
recovery scores were calculated similarly to the other cardiovascular variables by 
subtracting the early, middle and late recovery period values from the task average.  
Group (obese and non-obese) was used as a between-subjects factor; baseline 
values and reactivity scores were entered as covariates. Recovery from the CP task was 
analyzed first (Table 8). There was a significant main effect of period for HRV recovery 
from the CP task, due to violations of sphericity Greenhouse-Geisser corrections were 
used, F(2, 68) = 6.376, p = 0.009. Both groups showed an increase in HRV following the 
termination of the CP task. Collapsed across group, pairwise comparisons revealed HRV 
increased significantly from the early (mean = 0.799) to middle (mean = -7.644, p < 
0.000) as well as the middle to late (mean = -10.639, p = 0.036) recovery period. 
Recovery from the MA task was analyzed next. A significant main effect of group was 
found for SBP recovery, F(1, 36) = 4.230, p = .047) (Table 9). The average SBP recovery 
following the MA task was 5.0 for the obese group and 9.1 for the non-obese group. 
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Therefore, on average across the three recovery periods the obese group showed less SBP 
recovery from the MA task than the non-obese group. A significant interaction was 
present for HRV recovery from the MA task, F(2, 72) = 3.934, p = 0.024. The data 
revealed a similar increase in HRV in both groups from early to middle recovery. 
However, at the late recovery period obese group showed a decrease in HRV compared 
to the non-obese group. 
There were no other significant main effects or interactions for the recovery 
analysis on DBP or HR from either task. 
Salivary manipulation check  
Prior to evaluating reactivity difference between groups on salivary measures we 
first wanted to assess differences across time. Four repeated measures ANOVAs were 
used to investigate period differences on the salivary measures. All participants were 
entered into the analysis at once to provide an overall picture of response to the stress 
tasks. Level at baseline, tasks and recovery periods were evaluated for changes in levels 
of cortisol, interleukin-6, IgA and alpha-amylase (Figures 5).  
There was a significant effect of period for cortisol (F(1.948, 74.031) = 15.991, p 
< 0.000) and IgA (F(2.837, 102.117) = 6.147, p = 0.001). Follow up testing was done 
using t-tests to determine if the levels of cortisol and IgA during the stress tasks were 
significantly different from levels at their respective rest periods. For cortisol, 
participants had significantly elevated levels present during both of the stress tasks when 
compared to their respective rest periods (CP: t(38) = 4.295, p < 0.000; MA: t(38) = 
3.689, p = 0.001). For IgA, participants had significantly elevated levels during the MA 
task when compared to the subsequent rest period (t(39) = 3.987, p < 0.000); however the 
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level of IgA present during the CP task was not significantly different from the following 
rest period (t(30) = 1.912, p = 0.064).  
A significant period effect was not present for alpha-amylase (p = 0.075); 
however, the change over time was similar to that of cortisol and IgA, with both task 
levels being elevated relative to their respective rest periods. Period effect for interleukin-
6 was non-significant (p = 0.593) and did not show the pattern of response present among 
the other salivary measures. 
Analysis of salivary reactivity 
Aims two through four were achieved through analysis of the salivary measures. 
We wanted to know if there were group differences or interactions between obesity and 
reactivity to the two stress tasks. To assess reactivity in the salivary measures, repeated 
measures ANOVAs were performed. Reactivity scores for the two tasks were calculated 
for each participant by subtracting the baseline value from the task value. A grouping 
factor was use to separate participants into obese and non-obese groups. Salivary 
reactivity is presented in Figure 6. 
There was a significant interaction between group and task for cortisol (F(1, 37) = 
5.047, p = 0.030) (Table 10). Follow up analysis revealed a significant difference in 
cortisol reactivity between groups for the CP task (t(37) = -2.170, p = 0.010), but not the 
MA task (t(37) = .338, p = 0.737). The obese group had an exaggerated cortisol response 
to the CP task compared to the non-obese group. 
The interaction between group and task was also significant for alpha-amylase 
(F(1, 38) = 6.923, p = 0.012). Follow up analysis demonstrated marginally significant 
group differences in alpha-amylase reactivity to the MA task (t(30.356) = -2.034, p = 
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0.051), but not to the CP task (t(38) = 0.487), p = 0.629). The obese group responded to 
the MA task with greater alpha-amylase reactivity compared to the non-obese group. 
There were no significant main effects or interactions for task reactivity comparison by 
group for interleukin-6 or immunoglobulin-A.  
Analysis of salivary recovery 
In addition to reactivity differences among the salivary measures, we also wanted 
to know if there were group differences or interactions between obesity and tasks for 
recovery scores. Recovery differences between groups in salivary measures were 
investigated using repeated measures ANCOVAs. Separate analyses were performed for 
each task. Group (obese and non-obese) was used as a between-subjects factor and task 
value and the corresponding recovery value comprised the within-subjects factor; 
baseline values were entered as a covariate.  
None of the ANCOVAs revealed significant period (task and recovery) by group 
interactions. For the MA task, there was a significant main effect of period for both 
cortisol and IgA, F(1, 36) = 6.921, p = 0.012 and F(1, 37) = 6.957, p = 0.012, respectively 
(Table 12). As expected, cortisol and IgA task levels were higher than subsequent levels 
during the rest period. The interaction between period and group for IgA approached 
significance (p = 0.072). As shown in Figure 7f, the obese group shows a trend towards 
blunted reactivity.  
None of the other recovery analyses for salivary measures were significant (Table 
11). However, with few exceptions (cortisol recovery from the CP task and interleukin-6 
recovery from both tasks) a visual inspection of the graphs reveals a trend by both groups 
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in the expected direction. That is, that task levels were higher than levels during the rest 
period (Figure 7). 
Correlational analysis 
Aim five of the current study was accomplished through correlational analysis. 
This analysis was used to investigate relationships among cardiovascular, endocrine, and 
immune reactivity to the stress tasks. Changes scores were used for both the 
cardiovascular and salivary measures (e.g., task average minus baseline) allowing us to 
control for differences in baseline values. Correlations were computed separately for the 
obese and non-obese groups to determine differences in the relationships among 
cardiovascular and salivary measures; these correlations are displayed in Table 13. 
For the CP task there was a significant correlation for the obese group between 
SBP reactivity and cortisol (r = 0.495, p = 0.031). In the non-obese group there was a 
significant correlation between blood pressure reactivity and IgA (SBP, r = 0.448, p = 
0.048; DBP, r = 0.550, p = 0.012). These results suggest that for the CP task greater SPB 
reactivity was related to increased cortisol for the obese group. Although this relationship 
between cardiovascular reactivity and cortisol was not found in the non-obese group 
during the CP task, there was an association between blood pressure and IgA. Blood 
pressure reactivity to the CP task increased in non-obese participants, as did IgA.  
For the MA task the obese group showed a significant correlation between HR 
reactivity and cortisol (r = 0.615, p = 0.005). There was also a significant correlation 
between HR reactivity to the MA task and IgA (r = 0.504, p = 0.024) in the obese group. 
In the non-obese group, HR reactivity to the MA task was significantly correlated with 
cortisol (HR, r = 0.525, p = 0.018). Although the relationships between cardiovascular 
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reactivity and salivary response to the CP task were distinct between the obese and non-
obese groups, a different pattern emerged for the MA task. Both the obese and non-obese 
groups showed an increase in HR reactivity in response to the MA task that was 
significantly correlated to an increase in cortisol during the task. In addition, there was a 
significant relationship between HR reactivity and increased IgA during the MA task in 
the obese group.  
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V. DISCUSSION 
The present study was designed to examine differences between obese and non-
obese individuals in their cardiovascular, immune and endocrine response to two acute 
stress tasks. The CP and MA tasks were chosen because they represent different 
categories of stress (e.g., physical and psychological) and require distinct methods of 
coping (e.g., passive and active). The distinction between these two tasks comes about in 
part due to the different patterns of physiological arousal associated with each task.  
Prior to conducting our main analyses, group differences were assessed on a 
number of factors. As expected, participants in the obese group had significantly higher 
anthropometric measurements than the non-obese group. Several questionnaires were 
administered throughout the study to assess life stress, stress experienced during the 
tasks, pain experienced during the CP task and perceived effort on the MA task. There 
were no group differences present on any of these measures. The Brief COPE, a measure 
of coping strategy, was administered at the beginning of the study session. Group 
differences were found for two of the coping mechanisms: denial and behavioral 
disengagement. The obese group reported greater use of denial and behavioral 
disengagement in dealing with recent stressful events in their life. There were no 
differences found between groups for performance on the MA task, measured as total 
number of answers attempted or percent of correct responses. As expected, the obese 
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group had significantly higher baseline levels of SBP, DBP and HR compared to 
the non-obese group; as well as reduced HRV, though this was not significant. The obese 
group exhibited lower levels of cortisol and alpha-amylase at baseline. 
 The first aim of this project was to confirm previous findings from our lab in 
which obese participants had greater cardiovascular reactivity to passive stress, yet 
exhibit blunted reactivity to active stress. Further, we anticipated greater adiposity would 
result in delayed cardiovascular recovery following both of the stress tasks. Analysis 
revealed significant reactivity differences between groups. The obese group demonstrated 
greater blood pressure reactivity when averaged across tasks. We were able to confirm 
our hypothesis that obese participants would have exaggerated cardiovascular reactivity 
to passive stress. However, we failed to detect blunted reactivity in response to active 
stress.  
Our hypothesis of blunted reactivity was based on findings from our previous 
study (Burch & Allen, 2014). In that study, participants were instructed to subtract a two-
digit number from a four-digit number for the MA task. In the present study participants 
began with a three-digit number and subtracted by a one-digit number. This change may 
have resulted in the task being perceived as easier. If the task was perceived as achievable 
then the participant may have been actively engaged in an attempt to complete the task. 
This would suggest that the defeat reaction that may have resulted in the previously found 
blunted reactivity might not have been triggered in the current study. It is possible that 
there is a threshold of task stressfulness, and a perceived lack of resources to overcome 
the stressor, that must be met to cause blunted reactivity.     
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Changes in alpha-amylase were also assessed as a second measure of autonomic 
activation. As with blood pressure and HR, alpha-amylase increases as a result of 
sympathetic activation (Nater & Rohleder, 2009). A study conducted by Leslie, Putney 
and Sherman (1976) attempted to elucidate the mechanisms behind alpha-amylase 
secretion. By removing the parotid glands of rats they were able to quantify the effects of 
in vitro stimulation of alpha and beta-adrenergic receptors. Although the cells were 
responsive to both types of adrenergic stimulation (suggesting the presence of both types 
of receptors), they found that isoprenaline, a non-selective beta-adrenergic agonist, 
resulted in a significantly greater increase in alpha-amylase from the parotid tissue. 
Pharmacological studies in humans have corroborated these early findings in animals 
suggesting that alpha-amylase secretion is primarily stimulated by the activation of beta-
adrenergic receptors (van Stegeren et al., 2006).  
In the current study we found that in response to the MA task, the obese group 
had elevated levels of alpha-amylase compared to the non-obese group. This suggests 
that the obese group may be more sensitive to the beta-adrenergic activation that occurs 
as a result of the MA task. This finding is in opposition to our hypothesis of blunted 
sympathetic reactivity by the obese group in response to active stress. A rise in alpha-
amylase in response to psychological stress in the absence of a corresponding increase in 
cardiovascular measures have led some to posit that alpha-amylase is an acutely sensitive 
measure of the sympathetic stress response (van Stegeren et al., 2006).  
A review of the literature returned a single study evaluating the impact of obesity 
on alpha-amylase response to an acute stress task. In this study, the authors found no 
difference in alpha-amylase reactivity to an active stress task between an obese and non-
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obese group (Jayasinghe, Torres, Nowson, Tilbrook & Turner, 2014). However, the 
sample consisted entirely of older men and the mean BMI of the obese group was 30.6, 
compared to a mean BMI of 23.5 in the non-obese group. These findings together with 
the result of the current study suggest that there may be a gender difference in alpha-
amylase response to stress in obese individuals, with only obese females showing an 
exaggerated alpha-amylase stress response. Alternatively, a greater difference between 
BMI groups may be required for distinctions in the stress response to surface.    
Cardiovascular recovery from the two stress tasks was also evaluated as part of 
our first aim. We hypothesized that the obese group would have a delay in recovery 
following both of the stress tasks. Three time points during the recovery period were used 
to assess early, middle and late recovery for each of our cardiovascular measures. Two 
recovery analyses revealed significant group differences. Following the MA task, the 
obese group demonstrated blunted SBP and HRV recovery. When collapsed across early, 
middle and late recovery the obese group exhibited blunted SBP recovery compared to 
the non-obese group. Visual inspection of the data revealed that the non-obese group had 
fallen below their baseline SBP by the late recovery period. The obese group however 
failed to reach their baseline level of SBP, even by the late recovery period. For HRV, 
recovery was similar between the two groups for early and middle recovery; HRV was 
increasing in both groups following termination of the MA task. However, during the late 
recovery period the obese group did not continue to increase in HRV, but instead showed 
a decreasing trend. Thus we were able to affirm our hypothesis of a delayed 
cardiovascular recovery from the MA task although we were unable to identify 
differences in CP recovery.   
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The second aim of the current study was to evaluate HPA reactivity and recovery 
from the stress tasks, with a specific interest in difference between the obese and non-
obese groups. We hypothesized that the obese group would exhibit exaggerated HPA 
reactivity to the CP task and blunted reactivity to the MA task. Stimulation of the HPA 
axis, a system often activated concurrently with the sympathetic nervous system, results 
in the release of cortisol. Cortisol level at baseline was higher in both groups than at any 
subsequent period, including the samples taken immediately following the stress tasks. 
We are not sure why participants demonstrated elevated levels of cortisol at baseline. It is 
possible that the ten-minute rest period was not a sufficient amount of time to allow 
participants to reach a baseline level of cortisol. The obese group had lower basal levels 
of cortisol. Reactivity differences in cortisol, that took baseline differences into account, 
were also present. As anticipated the obese group had an exaggerated cortisol response to 
the CP task compared to the non-obese group. However, we were unable to identify 
group differences in cortisol response to the MA task.  
A diminished level of basal cortisol in obese individuals, or those with an elevated 
waist-to-hip ratio has been found by others (Salehi et al., 2005; Soros, Zadik, & Chalew, 
2008; Ljung, Andersson, Bengtsson, Björntorp, & Mårin, 1996). In response to stress, the 
effect of obesity on cortisol secretion has been mixed with findings of both exaggerated 
(Epel et al., 2000; Moyer et al., 1994) and blunted (Miller et al., 2013; Phillips, 
Roseboom, Carroll & de Rooij, 2012) cortisol reactivity in obese participants. Yet others 
have failed to find a relationship between cortisol reactivity to laboratory stress tasks and 
obesity (Brydon, 2011). All of these studies used stress tasks that would be classified as 
active stressors. We predicted a blunted cortisol response to active stress in the obese 
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compared to the non-obese group. Similar to the results of our cardiovascular variables 
we failed to detect blunted cortisol reactivity. It is possible that the same explanation is 
responsible for both results. That is, blunted reactivity will only manifest in situations 
where a threshold of perceived stressfulness is met. 
In response to stress we would expect some activation of the HPA axis and 
subsequent release of cortisol. The release of cortisol results in the inhibition of insulin 
and thus an increase in the level of glucose availability (Lambillotte & Henquin, 1997). 
The availability of glucose is important when the stress response requires action (e.g., 
fight or flight). However, in instances of stress activation that is best resolved by passive 
submission the exaggerated rise in cortisol and influx of unnecessary glucose can 
contribute to insulin resistance, a hallmark of the metabolic syndrome. The pattern of 
HPA response seen in the non-obese group, where the level of cortisol following the CP 
was lower than the level following the MA task, represents a more advantageous model 
of HPA reactivity. 
HPA recovery from the tasks was also evaluated. There was not a significant 
change in cortisol level following the CP task. In contrast, following the MA task cortisol 
dropped significantly from task level to level during the subsequent rest period. Based on 
these findings it appears that obesity is associated with increased exposure to cortisol 
through inappropriate reactivity to passive stress. 
Our third aim was to investigate changes in the level of interleukin-6 in response 
to different stressors. More specifically, we wanted to know if differences would be 
present between obese and non-obese individuals. Unfortunately, interleukin-6 data were 
 81 
missing for several participants, resulting in a considerable decrease in our ability to 
detect group differences. None of the interleukin-6 analyses produced significant results.  
Examining group differences in the immune response to stress tasks was our 
fourth aim. Due to the presence of stress hormone receptors on immune cells, elements of 
the immune system are particularly responsive to stress. The non-invasive collection of 
saliva allowed us to quantify the immune response to stress by assessing changes in the 
level of IgA. In healthy individuals IgA level typically increases in response to active 
stress (Isowa, Ohira, & Murashima, 2004; Ring et al., 2000; Ring et al., 1999; Willemsen, 
Carroll, Ring, & Drayson, 2002; Willemsen et al., 1998; Willemsen, Ring, McKeever, & 
Carroll, 2000; Winzer et al., 1999) and decreases in response to passive stress (Ring et 
al., 2000; Willemsen et al., 2002). Although not significant, visual inspection of the graph 
(Figure 6c) suggests that on average both groups were more responsive to the active 
stressor (MA).  
Analysis of immune reactivity was not significant. However, as predicted, both 
groups show a trend towards greater immune reactivity to the MA task compared to the 
CP task. Marginally significant group differences were found for immune recovery 
following the stress tasks. When averaged across group, the level of IgA dropped 
significantly during the rest period following the MA task. However, the obese group 
demonstrated blunted immune recovery compared to the decrease seen in the non-obese 
group. A significant decrease was not present for IgA recovery from the CP task, though 
both groups showed a decreasing trend. In addition, the obese group again showed a trend 
towards blunted recovery. 
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Although there has been some research into baseline differences of IgA in obese 
and non-obese groups, the investigation of IgA stress response differences are severely 
lacking. Confirmed by the current study, there do not appear to be differences, based on 
adiposity, in basal levels of IgA (Cieslak, Frost & Klentrou, 2003). Mounting evidence 
suggests that the immune system is compromised in obese individuals (for a review see 
Milner & Beck, 2012). Although immunological differences at baseline were not found 
between the obese and non-obese groups, recovery differences were present. It appears 
that the obese group showed less movement in immune response throughout the study 
when compared to the non-obese group. This lack of change may represent an 
unfavorable immune response. Blunted IgA response to stress in obese individuals 
warrants further investigation. The relationship between obesity and compromised 
immunity may be better demonstrated by an overall blunted immune response to 
challenge rather than differences in baseline parameters.  
The final and overarching aim of our study was to investigate relationships among 
cardiovascular, endocrine and immune responses to stress, with the intention of 
characterizing differences between obese and non-obese groups. In response to the CP 
task, the obese and non-obese group showed different patterns of associations between 
measures. For the non-obese group, blood pressure reactivity to the CP task was related 
to IgA reactivity. However, for the obese group cortisol was related to increased SPB 
activity in response to the CP task.  
Our hypothesis of exaggerated cardiovascular and HPA activity in response to 
passive stress in the obese group was confirmed. Further, we observed an association 
between the HPA and sympathetic nervous system response to passive stress in the obese 
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group. The damaging effects of stress hyper-reactivity, both of the cardiovascular and 
HPA axis have been described above. Here we conclude that for obese individuals the 
relationship between the sympathetic nervous system and the HPA axis may be a 
synergistic one that works together to contribute to a disproportionate response to a 
passive stress task. Indeed, a comprehensive review by Chrousos and Gold (1992) 
describes a “positive, reverberatory feedback loop so that activation of one system tends 
to activate the other as well” (p. 1246). Confirmation and investigation into the 
implications of this finding should be examined further.  
The immunological response to the CP task was similar between the obese and 
non-obese group. However, the rise in IgA in the non-obese group was related to the 
increase in blood pressure reactivity to the task. In response to passive stress the non-
obese group demonstrated significantly less cardiovascular (SBP) reactivity; yet, they 
exhibit a relationship between blood pressure and immune response to the task.  
Although the response to passive stress shows dissimilar patterns in the 
relationships among the variables, response to the active task shows a more congruent 
pattern between the groups. Both the obese and non-obese groups responded to the MA 
task with an increase in HR that was significantly related to level of cortisol. 
Additionally, the obese group exhibited an increase in IgA that was positively related to 
HR reactivity during the MA task.   
The similar HPA activation by active stress in both the obese and non-obese 
group suggests that this response may not be impaired in obese individuals. Further, level 
of cortisol was related to sympathetic activation in both groups during the task. It is 
important to consider that although the groups showed similar patterns of reactivity in 
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response to active stress the obese group demonstrated blunted cardiovascular recovery 
following the MA task. Additionally, although the obese group failed to show a 
relationship between immune and cardiovascular reactivity to passive stress, the 
relationship was present in response to active stress.  
The current study is not without limitations. Males were excluded despite a 
considerable amount of research indicating gender differences in stress reactivity (Allen, 
Stoney, Owens, & Matthews, 1993; Girdler, Turner, Sherwood, & Light, 1990; Lawler, 
Wilcox, & Anderson, 1995). Due to limited resources it was not feasible to obtain an 
adequate sample to evaluate gender differences. Additionally, a previous study from our 
laboratory found cardiovascular reactivity difference using a female population. We 
hoped to replicate these findings and therefore we chose to recruit only female 
participants. Future studies should investigate similar impairments of obesity on stress 
response in males.  
Saliva collection presented a number of challenges. Saliva was collected using the 
passive drool technique; to achieve collection participants would drool into a collection 
vial while investigators were present to ensure adequate collection. Based on 
cardiovascular measures taken during saliva collection, it appears that most participants 
experienced some sympathetic arousal, at least during the initial collection. Although the 
cardiovascular data recorded during this period was not used in the analysis, this response 
to saliva collection could have impacted some of the salivary measures. Participants also 
demonstrated considerable variation in the amount of time necessary to produce the 
required saliva volume. The quantity of salivary analytes present in saliva sample is 
influenced by collection duration (Beltzer et al., 2010). In an attempt to correct for these 
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variations, collection time was recorded and flow rates were calculated for each sample 
and used as a conversion factor in the appropriate analyses.  
We did not control for the potential effects of menstrual cycle. It is possible that 
menstrual phase may have an impact on some of the salivary measures, particularly 
cortisol. A final limitation of the current study was the lack of an assessment of physical 
fitness. In a study of 906 women, researchers found that self-reported fitness was related 
to less coronary artery disease and lower risk of other adverse cardiovascular events; 
despite obesity not being independently related to these outcomes (Wessel et al., 2004). 
There are a number of fitness measures that could be used, ranging from maximal oxygen 
uptake tests to self-report questionnaires used to quantify physical activity. Future studies 
examining obesity and cardiovascular function should consider including a measure of 
physical fitness.  
In conclusion, we found that in response to active stress, the relationship between 
HPA and sympathetic activation was similar for obese and non-obese groups. However, 
the obese group appears to have blunted sympathetic and parasympathetic recovery 
following active stress. Conversely, the response to passive stress was different between 
groups with the obese group demonstrating an overall greater stress response to the CP 
task. This response included exaggerated reactivity of both the sympathetic and HPA 
systems as measured by blood pressure and cortisol. Moreover, the increases in SBP and 
cortisol in response to passive stress were positively correlated in the obese participants. 
This suggests a possible link in obese individuals between the sympathetic and HPA 
systems when activated in response to passive stress. These results indicate that the 
presentation of an abnormal stress response may occur at different times based on the 
 86 
type of stress. In response to passive stress, obese individuals show an exaggerated stress 
response; whereas the impairment associated with active stress appears during recovery. 
 87 
 
 
 
 
 
 
 
 
 
 
 
VI. REFERENCES 
 88 
Abel, E. D., Litwin, S, E., & Sweeney, G. (2008). Cardiac remodeling in obesity. 
Physiological Reviews, 88(2), 389-419. 
Ackerman, K. D., Martino, M., Heyman, R., Moyna, N. M., & Rabin, B. S. (1998). 
Stressor-induced alteration of cytokine production in multiple sclerosis patients 
and controls. Psychosomatic Medicine, 60(4), 484-491. 
Adams, N., Lins, M. D., & Blizard, D. A. (1987). Contrasting effects of social stress and 
foot-shock on acute cardiovascular response in salt-sensitive rats. Behavioral and 
Neural Biology, 48(3), 368-381. 
Ader, R., & Cohen, N. (1975). Behaviorally conditioned immunosuppression. 
Psychosomatic Medicine, 37(4), 333-340. 
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006). Metabolic syndrome—a new 
world-wide definition. A consensus statement from the international diabetes 
federation. Diabetic Medicine, 23(5), 469-480. 
Aldwin, C. M., Sutton, K. J., Chiara, G., & Spiro, A. (1996). Age differenced in stress, 
coping, and appraisal: Findings from the normative aging study. The Journals of 
Gerontology Series B: Psychological Science and Social Sciences, 51(4), P179-
P188. 
Allen, M. T., Obrist, P. A., Sherwood, A., & Crowell, M. D. (1987). Evaluations of 
myocardial and peripheral vascular response during reaction time, mental 
arithmetic, and cold pressor task. Psychophysiology, 24(6), 648-656. 
Allen, M. T., Stoney, C. M., Owens, J. F., & Matthews, K. A. (1993). Hemodynamic 
adjustments to laboratory stress: the influence of gender and personality. 
Psychosomatic Medicine, 55(6), 505-517.  
 89 
Alpert, M. A. (2001). Obesity cardiomyopathy: pathophysiology and evolution of the 
clinical syndrome. The American Journal of the Medical Sciences, 321(4), 225–
236. 
Altemus, M., Rao, B., Dhabhar, F. S., Ding, W., & Granstein, R. D. (2001). Stress-
induced changes in skin barrier function in healthy women. Journal of 
Investigative Dermatology, 117(2), 309-317. 
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental 
disorders (4th ed., text rev.). Washington (DC): American Psychiatric 
Association. 
Andrén, L., & Hannson, L. (1981). Circulatory effects of stress in essential hypertension. 
Acta Medica Scandinavica, 209(S646), 69-72. 
Barker, L. E., Kirtland, K. A., Gregg, E. W., Geiss, L. S., & Thompson, T. J. (2011). 
Geographic distribution of diagnosed diabetes in the US: a diabetes belt. 
American Journal of Preventive Medicine, 40(4), 434-439. 
Barofsky, I., Fontaine, K. R., & Cheskin, L. J. (1997). Pain in the obese: impact on 
health-related quality-of-life. Annals of Behavioral Medicine, 19(4), 408-410. 
Baum, A., Davidson, L. M., Rectanus, E., & McArdle, S. (1987). Chronic stress as a 
factor in physiologic reactivity to challenge. Health Psychology, 6(3), 221. 
Bautista, L. E., Vera, L. M., Arenas, I. A., & Gamarra, G. (2004). Independent 
association between inflammatory markers (C-reactive protein, interleukin-6, and 
TNF-α) and essential hypertension. Journal of Human Hypertension, 19(2), 149-
154. 
 90 
Beltzer, E. K., Fortunato, C. K., Guaderrama, M. M., Peckins, M. K., Garramone, B. M., 
& Granger, D. A. (2010). Salivary flow and alpha-amylase: collection technique, 
duration, and oral fluid type. Physiology & behavior, 101(2), 289-296. 
Benschop, R. J., Brosschot, J. F., Godaert, G. L., De Smet, M. B., Geenen, R. I. N. I. E., 
Olff, M. I. R. A. N. D. A., ... & Ballieux, R. E. (1994). Chronic stress affects 
immunologic but not cardiovascular responsiveness to acute psychological stress 
in humans. American Journal of Physiology-Regulatory, Integrative and 
Comparative Physiology, 266(1), R75-R80. 
Benson, S., Arck, P. C., Tan, S., Mann, K., Hahn, S., Janssen, O. E., ... & Elsenbruch, S. 
(2009). Effects of obesity on neuroendocrine, cardiovascular, and immune cell 
responses to acute psychosocial stress in premenopausal women. 
Psychoneuroendocrinology, 34(2), 181-189. 
Berg, A. H., & Scherer, P. E. (2005). Adipose tissue, inflammation, and cardiovascular 
disease. Circulation Research, 96(9), 939-949. 
Besedovsky, H., del Rey, A., Sorkin, E., & Dinarello, C. A. (1986). Immunoregulatory 
feedback between interleukin-1 and glucocorticoid hormones. Science, 233(4764), 
652-654. 
Bhaskar, V., Yin, J., Mirza, A. M., Phan, D., Vanegas, S., Issafras, H., Michelson, K., 
Hunter, J. J., & Kantak, S. S. (2011). Monoclonal antibodies targeting IL-1 beta 
reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque 
formation in Apolipoprotein E-deficient mice. Atherosclerosis, 216(2), 313-320. 
Björntorp, P. (1997). Body fat distribution, insulin resistance, and metabolic diseases. 
Nutrition, 13(9), 795-803. 
 91 
Björntorp, P. (2001). Do stress reactions cause abdominal obesity and comorbidities?. 
Obesity Reviews, 2(2), 73-86. 
Björntorp, P., & Rosmond, R. (2000). Obesity and cortisol. Nutrition, 16(10), 924-936. 
Blech, M., Peter, D., Fischer, P., Bauer, M., Hafner, M., Zeeb, M., & Nar, H. (2012). One 
target-two different binding modes: Structural insights into gevokizumab and 
canakinumab interactions to interleukin-1β (IL-1β). Journal of Molecular 
Biology, 425(1), 94-111. 
Borhani, N. O. (1965). Changes and geographic distribution of mortality from 
cerebrovascular disease. American Journal of Public Health and the Nations 
Health, 55(5), 673-681. 
Bornstein, S. R., Uhlmann, K., Haidan, A., Ehrhart-Bornstein, M., & Scherbaum, W. A. 
(1997). Evidence for a novel peripheral action of leptin as a metabolic signal to 
the adrenal gland: leptin inhibits cortisol release directly. Diabetes, 46(7), 1235-
1238. 
Boyd, G. S., Koenigsberg, J., Falkner, B., Gidding, S., & Hassink, S. (2005). Effect of 
obesity and high blood pressure on plasma lipid levels in children and 
adolescents. Pediatrics, 116(2), 442-446. 
Brydon, L. (2011). Adiposity, leptin and stress reactivity in humans. Biological 
Psychology, 86(2), 114-120. 
Brydon, L., Edwards, S., Jia, H., Mohamed-Ali, V., Zachary, I., Martin, J. F., & Steptoe, 
A. (2005). Psychological stress activates interleukin-1β gene expression in human 
mononuclear cells. Brain, Behavior, and Immunity, 19(6), 540-546. 
 92 
Brydon, L., Edwards, S., Mohamed-Ali, V., & Steptoe, A. (2004). Socioeconomic status 
and stress-induced increases in interleukin-6. Brain, Behavior, and Immunity, 
18(3), 281-290. 
Burch A. E., & Allen, M. T. (2014). Stress task specific impairments of cardiovascular 
functioning in obese participants. International Journal of Psychophysiology. 
Buske-Kirschbaum, A., Ebrecht, M., & Hellhammer, D. H. (2010). Blunted HPA axis 
responsiveness to stress in atopic patients is associated with the acuity and 
severeness of allergic inflammation. Brain, Behavior, and Immunity, 24(8), 1347-
1353. 
Buske-Kirschbaum, A., von Auer, K., Krieger, S., Weis, S., Rauh, W., & Hellhammer, D. 
(2003). Blunted cortisol responses to psychosocial stress in asthmatic children: a 
general feature of atopic disease?. Psychosomatic Medicine, 65(5), 806-810. 
Caceres, C., & Burns, J. W. (1997). Cardiovascular reactivity to psychological stress may 
enhance subsequent pain sensitivity. Pain, 69(3), 237-244. 
Calabro, P., Chang, D. W., Willerson, J. T., & Yeh, E. T. (2005). Release of C-reactive 
protein in response to inflammatory cytokines by human adipocytes: linking 
obesity to vascular inflammation. Journal of the American College of Cardiology, 
46(6), 1112-1113.  
Carpenter, L. L., Gawuga, C. E., Tyrka, A. R., Lee, J. K., Anderson, G. M., & Price, L. 
H. (2010). Association between plasma IL-6 response to acute stress and early-
life adversity in healthy adults. Neuropsychopharmacology, 35(13), 2617-2623. 
 93 
Carroll, D., Phillips, A. C., & Der, G. (2008). Body mass index, abdominal adiposity, 
obesity, and cardiovascular reactions to psychological stress in a large community 
sample. Psychosomatic Medicine, 70(6), 653-660.  
Carroll, D., Phillips, A. C., Hunt, K., & Der, G. (2007). Symptoms of depression and 
cardiovascular reactions to acute psychological stress: Evidence from a 
population study. Biological Psychology, 75(1), 68-74. 
Carver, C. S. (1997). You want to measure coping but your protocol’s too long: Consider 
the Brief COPE. International Journal of Behavioral Medicine, 4, 92-100. 
Cassidy, A. E,. Bielak, L. F., Zhou, Y., Sheedy, P. F., Turner, S. T., Breen, J. F., Peyser, 
P. A. (2005). Progression of subclinical coronary atherosclerosis: does obesity 
make a difference? Circulation, 111(15), 1877–1882. 
Centers for Disease Control and Prevention. (2013, May 2). High blood pressure. 
Retrieved from http://www.cdc.gov/bloodpressure/ 
Chae, C. U., Lee, R. T., Rifai, N., & Ridker, P. M. (2001). Blood pressure and 
inflammation in apparently healthy men. Hypertension, 38(3), 399-403. 
Chida, Y., & Hamer, M. (2008). Chronic psychosocial factors and acute physiological 
response to laboratory-induced stress in healthy populations: A quantitative 
review of 30 years of investigations. Psychological Bulletin, 134(6), 829-855. 
Chrousos, G. P. (2000). Stress, chronic inflammation, and emotional and physical well-
being: concurrent effects and chronic sequelae. Journal of Allergy and Clinical 
Immunology, 106(5), S275-S291. 
 94 
Chrousos, G. P., & Gold, P. W. (1992). The concepts of stress and stress system 
disorders: overview of physical and behavioral homeostasis. Jama, 267(9), 1244-
1252. 
Cieslak, T. J., Frost, G., & Klentrou, P. (2003). Effects of physical activity, body fat, and 
salivary cortisol on mucosal immunity in children. Journal of Applied Physiology, 
95(6), 2315-2320. 
Cohen, S., Kamarck, T., & Mermelstein, R. (1983). A global measure of perceived stress. 
Journal of health and social behavior, 385-396. 
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, 
M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., & Caro, J. F. 
(1996). Serum immunoreactive-leptin concentrations in normal-weight and obese 
humans. New England Journal of Medicine, 334(5), 292-295. 
Cox, D. A., Vita, J. A., Treasure, C. B., Fish, R. D., Alexander, R. W., Ganz, P., & 
Selwyn, A. P. (1989). Atherosclerosis impairs flow-mediated dilation of coronary 
arteries in humans. Circulation, 80(3), 458-465. 
Davis, M. C., Matthews, K. A., & Twamley, E. W. (1999). Is life more difficult on Mars 
or Venus? A meta-analytic review of sex differences in major and minor life 
events. Annals of Behavioral Medicine, 21(1), 83-97. 
Davis, M. C., & Twamley, E. W. (1999). Body fat distribution and hemodynamic stress 
response in premenopausal obese women: A preliminary study. Health 
Psychology, 18(6), 625-633. 
 95 
Davy, K. P., & Hall, J. E. (2004). Obesity and hypertension: two epidemics or one? 
American Journal of Physiology-Regulatory, Integrative and Comparative 
Physiology, 286(5), R803-R813. 
Dinarello, C. A. (2010). IL‐1: Discoveries, controversies and future directions. European 
Journal of Immunology, 40(3), 599-606. 
Dishman, R. K., & Nakamura, Y. (2003). Blood pressure and muscle sympathetic nerve 
activity during cold pressor stress: Fitness and gender. Psychophysiology, 40(3), 
370-380. 
Elenkov, I. J., & Chrousos, G. P. (1999). Stress hormones, Th1/Th2 patterns, pro/anti-
inflammatory cytokines and susceptibility to disease. Trends in Endocrinology & 
Metabolism, 10(9), 359-368. 
Elenkov, I. J., Wilder, R. L., Chrousos, G. P., & Vizi, E. S. (2000). The sympathetic 
nerve-an integrative interface between two supersystems: the brain and the 
immune system. Pharmacological Reviews, 52(4), 595-638.  
Epel, E. S., McEwen, B., Seeman, T., Matthews, K., Castellazzo, G., Brownell, K. D., ... 
& Ickovics, J. R. (2000). Stress and body shape: stress-induced cortisol secretion 
is consistently greater among women with central fat. Psychosomatic medicine, 
62(5), 623-632. 
Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley III, J. 
L. (2009). Sex, gender, and pain: a review of recent clinical and experimental 
findings. The Journal of Pain, 10(5), 447-485. 
 96 
Finkelstein, E. A., Trogdon, J. G., Cohen, J. W., & Dietz, W. (2009). Annual medical 
spending attributable to obesity: payer-and service-specific estimates. Health 
Affairs, 28(5), w822-w831. 
Fitzgibbons, T. P., Kogan, S., Aouadi, M., Hendricks, G. M., Straubhaar, J., & Czech, M. 
P. (2011). Similarity of mouse perivascular and brown adipose tissues and their 
resistance to diet-induced inflammation. American Journal of Physiology-Heart 
and Circulatory Physiology, 301(4), H1425-H1437. 
Flower, L., Gray, R., Pinkney, J., & Mohamed-Ali, V. (2003). Stimulation of interleukin-
6 release by interleukin-1β from isolated human adipocytes. Cytokine, 21(1), 32-
37. 
Freedman, D. S., Dietz, W. H., Tang, R., Mensah, G. A., Bond, M. G., Urbina, E. M., 
Berenson, G. S. (2004). The relation of obesity throughout life to carotid intima-
media thickness in adulthood: the Bogalusa Heart Study. International Journal of 
Obesity and Related Metabolic Disorders, 28(1), 59–166. 
Funakoshi, Y., Ichiki, T., Ito, K., & Takeshita, A. (1999). Induction of interleukin-6 
expression by angiotensin II in rat vascular smooth muscle cells. Hypertension, 
34(1), 118-125. 
Fyhrquist, F., Metsärinne, K., & Tikkanen, I. (1995). Role of angiotensin II in blood 
pressure regulation and in the pathophysiology of cardiovascular disorders. 
Journal of Human Hypertension, 9, S19. 
Gianaros, P. J., & Sheu, L. K. (2009). A review of neuroimaging studies of stressor-
evoked blood pressure reactivity: Emerging evidence for a brain-body pathway to 
coronary heart disease risk. Neuroimage, 47(3), 922-936. 
 97 
Ginty, A. T., Phillips, A. C., Higgs, S., Heaney, J. L., & Carroll, D. (2012). Disordered 
eating behaviour is associated with blunted cortisol and cardiovascular reactions 
to acute psychological stress. Psychoneuroendocrinology, 37(5), 715-724. 
Ginty, A. T., Phillips, A. C., Roseboom, T. J., Carroll, D., & deRooij, S. R. (2012). 
Cardiovascular and cortisol reactions to acute psychological stress and cognitive 
ability in the Dutch Famine Birth Cohort Study. Psychophysiology, 49(3), 391-
400. 
Goldberg, I. J., Blaner, W. S., Vanni, T. M., Moukides, M., & Ramakrishnan, R. (1990). 
Role of lipoprotein lipase in the regulation of high density lipoprotein 
apolipoprotein metabolism. Studies in normal and lipoprotein lipase-inhibited 
monkeys. Journal of Clinical Investigation, 86(2), 463. 
Gump, B. B., & Matthews, K. A. (1999). Do background stressors influence reactivity to 
and recovery from acute stressors? Journal of Applied Social Psychology, 29(3), 
469-494. 
Hallbäck, M., Magnusson, G., & Weiss, L. (1974). Stress-induced ulcer in spontaneously 
hypertensive rats. Acta Physiol Scand, 91, 6-7. 
Hayano, J., Sakakibara, Y., Yamada, A., Yamada, M., Mukai, S., Fujinami, T., ... & 
Takata, K. (1991). Accuracy of assessment of cardiac vagal tone by heart rate 
variability in normal subjects. The American journal of cardiology, 67(2), 199-
204. 
Heim, C., Ehlert, U., & Hellhammer, D. H. (2000). The potential role of hypocortisolism 
in the pathophysiology of stress-related bodily disorders. 
Psychoneuroendocrinology, 25(1), 1-35. 
 98 
Heinz, A., Hermann, D., Smolka, M. N., Rieks, M., Gräf, K. J., Pöhlau, D., Kuhn, W., & 
Bauer, M. (2003). Effects of acute psychological stress on adhesion molecules, 
interleukins and sex hormones: implications for coronary heart disease. 
Psychopharmacology, 165(2), 111-117. 
Hellström, B., & Lundberg, U. (2000). Pain perception to the cold pressor test during the 
menstrual cycle in relation to estrogen levels and a comparison with men. 
Integrative Physiological and Behavioral Science, 35(2), 132-141. 
Heo, M., Allison, D. B., Faith, M. S., Zhu, S., & Fontaine, K. R. (2003). Obesity and 
quality of life: mediating effects of pain and comorbidities. Obesity Research, 
11(2), 209-216. 
Hoyert, D. L., & Xu, J. (2012). Deaths: preliminary data for 2011. Natl Vital Stat Rep, 
61(6), 1-65. 
Ilardo, C., Tonioli, A. M., Aimone-Gastin, I., Abdelmouttaleb, I., Gueant, J. L., & Desor, 
D. (2001). Effects of psycho-physical stress competitive rafting on saliva 
interleukin-1 beta. Stress and Health, 17(1), 9-15. 
Isowa, T., Ohira, H., & Murashima, S. (2004). Reactivity of immune, endocrine and 
cardiovascular parameters to active and passive acute stress. Biological 
Psychology, 65(2), 101-120. 
Jayasinghe, S. U., Torres, S. J., Nowson, C. A., Tilbrook, A. J., & Turner, A. I. (2014). 
Physiological responses to psychological stress: importance of adiposity in men 
aged 50–70 years. Endocrine connections, 3(3), 110-119. 
 99 
Jern, S., Bergbrant, A., Björntorp, P., & Hansson, L. (1992). Relation of central 
hemodynamics to obesity and body fat distribution. Hypertension, 19(6 Pt 1), 
520-527. 
Jick, T. D., & Mitz, L. F. (1986). Sex differences in work stress. Journal of Library 
Administration, 7(1), 135-152. 
Juge-Aubry, C. E., Somm, E., Giusti, V., Pernin, A., Chicheportiche, R., Verdumo, C., 
Rohner-Jeanrenaud, F., Burger, D., Dayer, J., & Meier, C. A. (2003). Adipose 
tissue is a major source of interleukin-1 receptor antagonist upregulation in 
obesity and inflammation. Diabetes, 52(5), 1104-1110. 
Katzmarzyk, P. T.,  Janssen, I., & Ardern, C. I. (2003). Physical inactivity, excess 
adiposity and premature mortality. Obesity Reviews, 4(4), 257-290. 
Kelly, J. J., Mangos, G., Williamson, P. M., & Whitworth, J. A. (1998). Cortisol and 
hypertension. Clinical and Experimental Pharmacology and Physiology, 25(S1), 
S51-S56.  
Kenchaiah, S., Evans, J.C., Levy, D., Wilson, P.W., Benjamin, E.J., Larson, M.G., 
Kannel, W.B., & Vasan, R.S. (2002). Obesity and the risk of heart failure. New 
England Journal of Medicine, 347(5), 305–313. 
Keogh, E., Bond, F. W., Hanmer, R., & Tilston, J. (2005). Comparing acceptance-and 
control-based coping instructions on the cold-pressor pain experiences of healthy 
men and women. European Journal of Pain, 9(5), 591-598. 
Kirschbaum, C., & Hellhammer, D. H. (1989). Salivary cortisol in psychobiological 
research: an overview. Neuropsychobiology, 22(3), 150-169.  
 100 
Koo-Loeb, J. H., Pedersen, C., & Girdler, S. S. (1998). Blunted cardiovascular and 
catecholamine stress reactivity in women with bulimia nervosa. Psychiatry 
Research, 80(1), 13-27. 
Kompiang, I. P., Bensadoun, A., & Yang, M. W. (1976). Effect of an anti-lipoprotein 
lipase serum on plasma triglyceride removal. Journal of Lipid Research, 17(5), 
498-505. 
Kopelman, P. G., Grossman, A., Lavender, P., Besser, G. M., Rees, L. H., & Coy, D. 
(1988). The cortisol response to corticotrophin-releasing factor is blunted in 
obesity. Clinical Endocrinology, 28(1), 15-18. 
Kovalovsky, D., Refojo, D., Holsboer, F., & Arzt, E. (2000). Molecular mechanisms and 
Th1/Th2 pathways in corticosteroid regulation of cytokine production. Journal of 
Neuroimmunology, 109(1), 23-29. 
Krantz, D. S., & Manuck, S. B. (1984). Acute psychophysiological reactivity and risk of 
cardiovascular disease: A review and methodological critique. Psychological 
Bulletin, 96(3), 435-464. 
Lagathu, C., Yvan-Charvet, L., Bastard, J. P., Maachi, M., Quignard-Boulange, A., 
Capeau, J., & Caron, M. (2006). Long-term treatment with interleukin-1β induces 
insulin resistance in murine and human adipocytes. Diabetologia, 49(9), 2162-
2173. 
Lakka, T.A., Lakka, H.M., Salonen, R., Kaplan, G.A., & Salonen, J.T. (2001). 
Abdominal obesity is associated with accelerated progression of carotid 
atherosclerosis in men. Atherosclerosis, 154(2), 497–504. 
 101 
Lambillotte, C. G. P., & Henquin, J. C. (1997). Direct glucocorticoid inhibition of insulin 
secretion. An in vitro study of dexamethasone effects in mouse islets. Journal of 
Clinical Investigation, 99(3), 414. 
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., ... & 
Donath, M. Y. (2007). Interleukin-1–receptor antagonist in type 2 diabetes 
mellitus. New England Journal of Medicine, 356(15), 1517-1526. 
Lee, D. L., Sturgis, L. C., Labazi, H., Osborne, J. B., Fleming, C., Pollock, J. S., 
Manhiani, M., Imig, J. D., & Brands, M. W. (2006). Angiotensin II hypertension 
is attenuated in interleukin-6 knockout mice. American Journal of Physiology-
Heart and Circulatory Physiology, 290(3), H935-H940. 
Lepore, S. J., Miles, H. J., & Levy, J. S. (1997). Relation of chronic and episodic 
stressors to psychological distress, reactivity, and health problems. International 
Journal of Behavioral Medicine, 4(1), 39-59. 
Leslie, B. A., Putney, J. W., & Sherman, J. M. (1976). alpha-Adrenergic, beta-adrenergic 
and cholinergic mechanisms for amylase secretion by rat parotid gland in vitro. 
The Journal of physiology, 260(2), 351-370. 
Levy, D., Anderson, K. M., Savage, D. D., Kannel, W. B., Christiansen, J. C., & Castelli, 
W. P. (1988). Echocardiographically detected left ventricular hypertrophy: 
prevalence and risk factorsThe Framingham Heart Study. Annals of Internal 
Medicine, 108(1), 7-13. 
Ljung, T., Andersson, B., Bengtsson, B. Å., Björntorp, P., & Mårin, P. (1996). Inhibition 
of Cortisol Secretion by Dexamethasone in Relation to Body Fat Distribution: A 
Dose-Response Study. Obesity Research, 4(3), 277-282. 
 102 
Lovallo, W. R. (2010). Do low levels of stress reactivity signal poor states of health? 
Biological Psychology, 86(2), 121-128. 
Lovallo, W. R., & Gerin, W. (2003). Psychophysiological reactivity; mechanisms and 
pathways to cardiovascular disease. Psychosomatic Medicine, 65(1), 36-45. 
MacMahon, S. W., Wilcken, D. E., & Macdonald, G. J. (1986). The effect of weight 
reduction on left ventricular mass. New England Journal of Medicine, 314(6), 
334-339. 
Maier, S. F. (2003). Bi-directional immune–brain communication: implications for 
understanding stress, pain, and cognition. Brain, Behavior, and Immunity, 17(2), 
69-85. 
Mancini, T., Kola, B., Mantero, F., Boscaro, M., & Arnaldi, G. (2004). High 
cardiovascular risk in patients with Cushing’s syndrome according to 1999 
WGO/ISH guidelines. Clinical Endocrinology, 61(6), 768-777.  
Mandrup-Poulsen, T., Bendtzen, K., Nerup, J., Dinarello, C. A., Svenson, M., & Nielsen, 
J. H. (1986). Affinity-purified human interleukin I is cytotoxic to isolated islets of 
Langerhans. Diabetologia, 29(1), 63-67. 
Marshall Jr, G. D. (2011). The adverse effects of psychological stress on 
immunoregulatory balance: applications to human inflammatory diseases. 
Immunology and Allergy Clinics of North America, 31(1), 133. 
Martin, S. S., Qasim, A., & Reilly, M. P. (2008). Leptin resistance: A possible interface 
of inflammation and metabolism in obesity-related cardiovascular disease. 
Journal of the American College of Cardiology, 52(15), 1201-1210. 
 103 
Mastrolonardo, M., Alicino, D., Zefferino, R., Pasquini, P., & Picardi, A. (2007). Effect 
of Psychological Stress on Salivary Interleukin-1β in Psoriasis. Archives of 
Medical Research, 38(2), 206-211. 
Matthews, K. A. (2004). Blood pressure reactivity to psychological stress predicts 
hypertension in the CARDIA study. Circulation, 110(1), 74-78. 
McEwen, B. S. (2007). Physiology and neurobiology of stress and adaptation: Central 
role of the brain. Physiological Reviews, 87(3), 873–904. 
McKendall, M. J., & Haier, R. J. (1983). Pain sensitivity and obesity. Psychiatry 
Research, 8(2), 119-125. 
Mensah, G. A. (2004). Obesity, metabolic syndrome, and type 2 diabetes: emerging 
epidemics and their cardiovascular implications. Cardiology Clinics, 22(4), 485-
504. 
Miller, A. L., Clifford, C., Sturza, J., Rosenblum, K., Vazquez, D. M., Kaciroti, N., & 
Lumeng, J. C. (2013). Blunted cortisol response to stress is associated with higher 
body mass index in low-income preschool-aged children. 
Psychoneuroendocrinology, 38(11), 2611-2617. 
Milner, J. J., & Beck, M. A. (2012). The impact of obesity on the immune response to 
infection. Proceedings of the Nutrition Society, 71(02), 298-306. 
Moreno, J. J., & Mitjavila, M. T. (2003). The degree of unsaturation of dietary fatty acids 
and the development of atherosclerosis (review). The Journal of Nutritional 
Biochemistry, 14(4), 182-195. 
 104 
Moschen, A. R., Molnar, C., Enrich, B., Geiger, S., Ebenbichler, C. F., & Tilg, H. (2011). 
Adipose and liver expression of interleukin (IL)-1 family members in morbid 
obesity and effects of weight loss. Molecular Medicine, 17(7-8), 840.  
Moyer, A. E., Rodin, J., Grilo, C. M., Cummings, N., Larson, L. M., & Rebuffé-Scrive, 
M. (1994). Stress-Induced Cortisol Response and Fat Distribution in Women. 
Obesity research, 2(3), 255-262. 
Moynihan, J. A. (2003). Mechanisms of stress-induced modulation of immunity. Brain, 
Behavior, and Immunity, 17(1), 11-16. 
Nater, U. M., & Rohleder, N. (2009). Salivary alpha-amylase as a non-invasive 
biomarker for the sympathetic nervous system: current state of research. 
Psychoneuroendocrinology, 34(4), 486-496. 
Nonogaki, K., Fuller, G. M., Fuentes, N. L., Moser, A. H., Staprans, I., Grunfeld, C., & 
Feingold, K. R. (1995). Interleukin-6 stimulates hepatic triglyceride secretion in 
rats. Endocrinology, 136(5), 2143-2149. 
Obrist, P. A. Cardiovascular psychophysiology: A perspective. New York: Plenum Press, 
1981. Print. 
Oswald, L. M., Zandi, P., Nestadt, G., Potash, J. B., Kalaydjian, A. E., & Wand, G. S. 
(2006). Relationship between cortisol responses to stress and personality. 
Neuropsychopharmacology, 31(7), 1583-1591. 
Ottosson, M., Vikman-Adolfsson, K., Enerbäck, S., Olivecrona, G., & Björntorp, P. 
(1994). The effects of cortisol on the regulation of lipoprotein lipase activity in 
human adipose tissue. Journal of Clinical Endocrinology & Metabolism, 79(3), 
820-825.  
 105 
Owyang, A. M., Issafras, H., Corbin, J., Ahluwalia, K., Larsen, P., Pongo, E., Handa, M., 
Horwitz, A. H., Roell, M. K., Haak-Frendscho, M., & Masat, L. (2011). XOMA 
052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-
mediated diseases. mAbs, 3(1), 49-60.  
Owyang, A. M., Maedler, K., Gross, L., Yin, J., Esposito, L., Shu, L., Jadhav, J., 
Domsgen, E., Bergmann, J., Lee, S., & Kantak, S. (2010). XOMA 052, an anti-
IL-1β monoclonal antibody, improves glucose control and β-cell function in the 
diet-induced obesity mouse model. Endocrinology, 151(6), 2515-2527. 
Paccaud, F., Schlüter-Fasmeyer, V., Wietlisbach, V., & Bovet, P. (2000). Dyslipidemia 
and abdominal obesity: an assessment in three general populations. Journal of 
Clinical Epidemiology, 53(4), 393-400. 
Pace, T., Mletzko, T., Alagbe, O., Musselman, D., Nemeroff, C., Miller, A., & Heim, C. 
(2006). Increased stress-induced inflammatory responses in male patients with 
major depression and increased early life stress. American Journal of Psychiatry, 
163(9), 1630-1633. 
Pallaro, A., Barbeito, S., Taberner, P., Marino, P., Franchello, A., Strasnoy, I., Ramos, 
O., & Slobodianik. (2002). Total salivary IgA, serum C3c and IgA in obese 
school children. The Journal of Nutritional Biochemistry, 13(9), 539-542. 
Palmer, J. P., Helqvist, S., Spinas, G. A., Mølvig, J., Mandrup-Poulsen, T., Andersen, H. 
U., & Nerup, J. (1989). Interaction of β-cell activity and IL-1 concentration and 
exposure time in isolated rat islets of Langerhans. Diabetes, 38(10), 1211-1216. 
Papanicolaou, D. A., Petrides, J. S., Tsigos, C., Bina, S., Kalogeras, K. T., Wilder, R., ... 
& Chrousos, G. P. (1996). Exercise stimulates interleukin-6 secretion: inhibition 
 106 
by glucocorticoids and correlation with catecholamines. American Journal of 
Physiology-Endocrinology And Metabolism, 271(3), E601-E605. 
Pasquali, R., Anconetani, B., Chattat, R., Biscotti, M., Spinucci, G., Casimirri, F., 
Vicennati, V., Carcello, A., & Labate, A. M. (1996). Hypothalamic-pituitary-
adrenal axis activity and its relationship to the autonomic nervous system in 
women with visceral and subcutaneous obesity: effects of the corticotropin-
releasing factor/arginine-vasopressin test and of stress. Metabolism: Clinical and 
Experimental, 45(3), 351. 
Paunovic, K., Jakovljevic, B., & Stojanov, V. (2006). Left ventricular hypertrophy in 
hypertensive obese women. Acta Cardiologica, 61(6), 623-629. 
Peckerman, A., Saab, P. G., McCabe, P. M., Skyler, J. S., Winters, R. W., Llabre, M. M., 
& Schneiderman, N. (1991). Blood pressure reactivity and perception of pain 
during the forehead cold pressor test. Psychophysiology, 28(5), 485-495. 
Phillips, A. C. (2011). Blunted cardiovascular reactivity relates to depression, obesity, 
and self-reported health. Biological Psychology, 86(2), 106-113. 
Phillips, A. C., Hunt, K., Der, G., & Carroll, D. (2011). Blunted cardiac reactions to acute 
psychological stress predict symptoms of depression five years later: Evidence 
from a large community study. Psychophysiology, 48(1), 142-148. 
Phillips, A. C., Roseboom, T. J., Carroll, D., & de Rooij, S. R. (2012). Cardiovascular 
and cortisol reactions to acute psychological stress and adiposity: cross-sectional 
and prospective associations in the Dutch Famine Birth Cohort Study. 
Psychosomatic medicine, 74(7), 699-710. 
 107 
Piché, M. È., Lemieux, S., Weisnagel, S. J., Corneau, L., Nadeau, A., & Bergeron, J. 
(2005). Relation of high-sensitivity C-reactive protein, interleukin-6, tumor 
necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, 
and cholesterol and triglyceride levels in healthy postmenopausal women. The 
American Journal of Cardiology, 96(1), 92. 
Pralong, F. P., Roduit, R., Waeber, G., Castillo, E., Mosimann, F., Thorens, B., & 
Gaillard, R. C. (1998). Leptin inhibits directly glucocorticoid secretion by normal 
human and rat adrenal gland. Endocrinology, 139(10), 4264-4268. 
Rabbitt, P., Donlan, C., Watson, P., McInnes, L., & Bent, N. (1995). Unique and 
interactive effects of depression, age, socioeconomic advantage, and gender on 
cognitive performance of normal healthy older people. Psychology and Aging, 
10(3), 307. 
Racine, M., Tousignant-Laflamme, Y., Kloda, L. A., Dion, D., Dupuis, G., & Choinière, 
M. (2012). A systematic literature review of 10years of research on sex/gender 
and experimental pain perception–Part 1: Are there really differences between 
women and men?. Pain, 153(3), 602-618. 
Ramzan, I., Wong, B. K., & Corcoran, G. B. (1993). Pain sensitivity in dietary-induced 
obese rats. Physiology & Behavior, 54(3), 433-435. 
Ravnkilde, B., Videbech, P., Clemmensen, K., Egander, A., Rasmussen, N. A., & 
Rosenberg, R. (2002). Cognitive deficits in major depression. Scandinavian 
Journal of Psychology, 43(3), 239-251. 
 108 
Reisin, E., Frohlich, E. D., Messerli, F. H., Dreslinski, G. R., Dunn, F. G., Jones, M. M., 
& Batson, H. M. (1983). Cardiovascular changes after weight reduction in obesity 
hypertension. Annals of Internal Medicine, 98(3), 315-319. 
Ring, C., Carroll, D., Willemsen, G., Cooke, J., Ferraro, A., & Drayson, M. (1999). 
Secretory immunoglobulin A and cardiovascular activity during mental arithmetic 
and paced breathing. Psychophysiology, 36(5), 602-609. 
Ring, C., Harrison, L. K., Winzer, A., Carroll, D., Drayson, M., & Kendall, M. (2000). 
Secretory immunoglobulin A and cardiovascular reactions to mental arithmetic, 
cold pressor, and exercise: Effects of alpha-­‐adrenergic blockade. 
Psychophysiology, 37(5), 634-643. 
Ritchie, S. A., & Connell J. M. C. (2007). The link between abdominal obesity, metabolic 
syndrome and cardiovascular disease. Nutrition, Metabolism and Cardiovascular 
Diseases, 17(4), 319–326. 
Roytblat, L., Rachinsky, M., Fisher, A., Greemberg, L., Shapira, Y., Douvdevani, A., & 
Gelman, S. (2000). Raised Interleukin-­‐6 Levels in Obese Patients. Obesity 
Research, 8(9), 673-675. 
Salehi, M., Ferenczi, A., & Zumoff, B. (2005). Obesity and cortisol status. Hormone and 
Metabolic Research, 37(04), 193-197. 
Scarim, A. L., Heitmeier, M. R., & Corbett, J. A. (1997). Irreversible inhibition of 
metabolic function and islet destruction after a 36-hour exposure to interleukin-
1β. Endocrinology, 138(12), 5301-5307. 
Schmaus, B. J., Laubmeier, K. K., Boquiren, V. M., Herzer, M., & Zakowski, S. G. 
(2008). Gender and stress: differential psychophysiological reactivity to stress 
 109 
reexposure in the laboratory. International Journal of Psychophysiology, 69(2), 
101-106. 
Schwartz, A. R. (2003). Toward a causal model of cardiovascular response to stress and 
the development of cardiovascular disease. Psychosomatic Medicine, 65(1), 22-
35. 
Sharpley, C. F., & Gordon, J. E. (1999). Differences between ECG and pulse when 
measuring heart rate and reactivity under two physical and two psychological 
stressors. Journal of Behavioral Medicine, 22(3), 285-301. 
Sherwood, A., Allen, M. T., Obrist, P. A., & Langer, A. W. (1986). Evaluation of beta-
adrenergic influences on cardiovascular and metabolic adjustments to physical 
and psychological stress. Psychophysiology, 23(1), 89-104. 
Silva, A. (2009). Role of sympathetic nervous system in obesity-related hypertension. 
Current Hypertension Reports, 11(3), 206-211. 
Singer, G., & Granger, D. N. (2007). Inflammatory responses underlying the 
microvascular dysfunction associated with obesity and insulin resistance. 
Microcirculation, 14(4-5), 375-387. 
Sompayrac, L. (2003). How the immune system works. (4th ed.). West Sussex, UK: 
Blackwell. 
Soros, A., Zadik, Z., & Chalew, S. (2008). Adaptive and maladaptive cortisol responses 
to pediatric obesity. Medical hypotheses, 71(3), 394-398. 
Speaker, K. J., & Fleshner, M. (2012). Interleukin-1 beta: a potential link between stress 
and the development of visceral obesity. BMC Physiology, 12(1), 8. 
 110 
Spinas, G. A., Mandrup-Poulsen, T., Mølvig, J., Bæk, L., Bendtzen, K., Dinarello, C. A., 
& Nerup, J. (1986). Low concentrations of interleukin-1 stimulate and high 
concentrations inhibit insulin release from isolated rat islets of Langerhans. Acta 
Endocrinologica, 113(4), 551-558. 
Srinivasan, S. R., Myers, L., & Berenson, G. S. (1999). Temporal association between 
obesity and hyperinsulinemia in children, adolescents, and young adults: the 
Bogalusa Heart Study. Metabolism: Clinical and Experimental, 48(7), 928. 
Stapleton, P. A., James, M. E., Goodwil, A. G., & Frisbee, J. C. (2008). Obesity and 
vascular dysfunction. Pathophysiology,15(2), 79-89. 
Steptoe, A. (2005). Cardiovascular stress responsivity, body mass and abdominal 
adiposity. International Journal of Obesity, 29(11), 1329-1337. 
Steptoe, A., Hamer, M., & Chida, Y. (2007). The effects of acute psychological stress on 
circulating inflammatory factors in humans: A review and meta-analysis. Brain, 
Behavior, and Immunity, 21(7), 901-912. 
Steptoe, A., Willemsen, G., Owen, N., Flower, L., & Mohamed-Ali, V. (2001). Acute 
mental stress elicits delayed increases in circulating inflammatory cytokine levels. 
Clinical Science, 101(2), 185-192.  
Sternberg, E. M. (1997). Neural-immune interactions in health and disease. Journal of 
Clinical Investigation, 100(11), 2641. 
Styne, D. M., Grumbach, M. M., Kaplan, S. L., Wilson, C. B., & Conte, F. A. (1984). 
Treatment of Cushing's disease in childhood and adolescence by transsphenoidal 
microadenomectomy. New England Journal of Medicine, 310(14), 889-893. 
 111 
Strömgren, L. (1977). The influence of depression on memory. Acta Psychiatrica 
Scandinavica, 56(2), 109-128. 
Thoma, M. V., Kirschbaum, C., Wolf, J. M., & Rohleder, N. (2012). Acute stress 
responses in salivary alpha-amylase predict increases of plasma norepinephrine. 
Biological psychology, 91(3), 342-348. 
Trujillo, M. E., Sullivan, S., Harten, I., Schneider, S. H., Greenberg, A. S., & Fried, S. K. 
(2004). Interleukin-6 regulates human adipose tissue lipid metabolism and leptin 
production in vitro. Journal of Clinical Endocrinology & Metabolism, 89(11), 
5577-5582. 
Van Gaal, L. F., Mertens, I. L., & Block, C. E. (2006). Mechanisms linking obesity with 
cardiovascular disease. Nature, 444(7121), 875-880. 
van Stegeren, A., Rohleder, N., Everaerd, W., & Wolf, O. T. (2006). Salivary alpha 
amylase as marker for adrenergic activity during stress: effect of betablockade. 
Psychoneuroendocrinology, 31(1), 137-141. 
Vogelzangs, N., Beekman, A. T., Milaneschi, Y., Bandinelli, S., Ferrucci, L., & Penninx, 
B. W. (2010). Urinary cortisol and six-year risk of all-cause and cardiovascular 
mortality. Journal of Clinical Endocrinology & Metabolism, 95(11), 4959-4964.  
Voudoukis, I. J. (1970). Exaggerated cold-pressor response in hypertensive patients with 
superimposed arteriosclerosis. Surgical Oncology, 2(1), 83-87. 
Vybiral, T., Bryg, R. J., Maddens, M. E., & Boden, W. E. (1989). Effect of passive tilt on 
sympathetic and parasympathetic components of heart rate variability in normal 
subjects. The American journal of cardiology, 63(15), 1117-1120. 
 112 
Waage, A., Slupphaug, G., & Shalaby, R. (1990). Glucocorticoids inhibit the production 
of IL 6 from monocytes, endothelial cells and fibroblasts. European Journal of 
Immunology, 20(11), 2439-2443. 
Wang, Z., & Nakayama, T. (2010). Inflammation, a link between obesity and 
cardiovascular disease. Mediators of Inflammation, 19(3), 517-521. 
Weinberg, C. R., & Pfeifer, M. A. (1984). An improved method for measuring heart-rate 
variability: assessment of cardiac autonomic function. Biometrics, 855-861. 
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. 
W. (2003). Obesity is associated with macrophage accumulation in adipose tissue. 
Journal of Clinical Investigation, 112(12), 1796-1808. 
Wessel, T. R., Arant, C. B., Olson, M. B., Johnson, B. D., Reis, S. E., Sharaf, B. L., ... & 
Merz, C. N. B. (2004). Relationship of physical fitness vs body mass index with 
coronary artery disease and cardiovascular events in women. Jama, 292(10), 
1179-1187. 
Willemsen, G., Carroll, D., Ring, C., & Drayson, M. (2002). Cellular and mucosal 
immune reactions to mental and cold stress: Associations with gender and 
cardiovascular reactivity. Psychophysiology, 39(2) 222-228. 
Willemsen, G, Ring, C., Carroll, D., Evans, P., Clow, A., & Hucklebridge, F. (1998). 
Secretory immunoglobulin A and cardiovascular reaction to mental arithmetic and 
cold pressor. Psychophysiology, 35(3), 252-259.  
Willemsen, G., Ring, C., McKeever, S., & Carroll, D. (2000). Secretory immunoglobulin 
A and cardiovascular activity during mental arithmetic: effects of task difficulty 
and task order. Biological Psychology, 52(2), 127-141.  
 113 
Wilson, P. W., D'Agostino, R. B., Sullivan, L., & Parise, H. (2002). Overweight and 
obesity as determinants of cardiovascular risk: the Framingham experience. 
Archives of Internal Medicine, 162(16), 1867-1872. 
Winzer, A., Ring, C., Carroll, D., Willemsen, G., Drayson, M., & Kendall, M. (1999). 
Secretory immunoglobulin A and cardiovascular reactions to mental arithmetic, 
cold pressor, and exercise: Effects of beta-adrenergic blockade. 
Psychophysiology, 36(5), 591-601. 
World Health Organization. (2013, March). Obesity and overweight. Retrieved from 
http://www.who.int/mediacentre/factsheets/fs311/en/ 
Xiang, L., Del Ben, K. S., Rehm, K. E., & Marshall, G. D. (2011). Effects of acute stress-
induced immunomodulation on Th1/Th2 cytokine and catecholamine receptor 
expression in human peripheral blood cells. Neuropsychobiology, 65(1), 12-19.  
Xu, H. (2013). Obesity and metabolic inflammation. Drug Discovery Today: Disease 
Mechanisms, 10(1), e21-e25.  
Yudkin, J. S., Kumari, M., Humphries, S. E., & Mohamed-Ali, V. (2000). Inflammation, 
obesity, stress and coronary heart disease: is interleukin-6 the link? 
Atherosclerosis, 148(2), 209-214.  
Zahorska-Markiewicz, B., Zych, P., & Kucio, C. (1988). Pain sensitivity in obesity. Acta 
Physiologica Polonica, 39(3), 183. 
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J.M. (1994). 
Positional cloning of the mouse obese gene and its human homologue. Nature, 
372(6505), 425-432. 
 114 
Zhou, D. A. O. H. O. N. G., Kusnecov, A. W., Shurin, M. R., DePaoli, M., & Rabin, B. 
S. (1993). Exposure to psychical and psychological stressors elevates plasma 
interleukin 6: relationship to the activation of the hypothalamic-pituitary-adrenal 
axis. Endocrinology, 133(6), 2523-2530. 
Ziccardi, P., Nappo, F., Giugliano, G., Esposito, K., Marfella, R., Cioffi, M., ... & 
Giugliano, D. (2002). Reduction of inflammatory cytokine concentrations and 
improvement of endothelial functions in obese women after weight loss over one 
year. Circulation, 105(7), 804-809. 
Zuliani, G., Volpato, S., Blè, A., Bandinelli, S., Corsi, A. M., Lauretani, F., Paolisso, G., 
Fellin, R., & Ferrucci, L. (2007). High interleukin-6 plasma levels are associated 
with low HDL-C levels in community-dwelling older adults: the InChianti study. 
Atherosclerosis, 192(2), 384-390. 
 
 
 
 115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII. APPENDIX 
 
 116 
Table 1. Group means and standard deviations (SD) for anthropometric measures 
 
Obese Non-Obese  
Mean SD Mean SD 
BMI** 41.9 7.2 22.3 1.6 
WC (in)** 46.7 6.5 31.8 2.4 
WHR** 0.9 0.1 0.8 0.05 
Weight (lbs)** 225.2 54.5 133.3 11.3 
Notes: BMI = body mass index, WC = waist circumference, WHR = waist to hip ratio. 
* p < .05 
** p < .01 
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Table 2. Group means and standard deviations (SD) for questionnaires 
 
Obese Non-Obese  
Mean SD Mean SD 
PSS 17.7 5.4 15.8 5.6 
CP Stress 3.7 2.0 3.9 2.0 
MA Stress 5.3 2.0 4.6 1.9 
CP Pain Minute 1 4.1 2.6 4.3 2.2 
CP Pain Minute 4 3.9 2.6 3.5 1.5 
MA Effort 7.5 1.5 6.9 1.3 
Notes: PSS = Perceived Stress Scale, CP = cold pressor, MA = mental arithmetic. 
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Table 3. Group means and standard deviations (SD) on MA performance 
 
Obese Non-obese  
Mean SD Mean SD 
Total Responses 
Attempted 
64.95 49.1 52.3 30.8 
Percent of Correct 
Responses 
85 13 81 17 
Notes: MA = mental arithmetic. 
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Table 4. Group means and standard deviations (SD) for baseline cardiovascular measures 
 
Obese Non-Obese  
Mean SD Mean SD 
SBP** 125.3 9.1 113.6 8.7 
DBP* 74.1 5.8 70.1 5.9 
HR* 82.2 10.8 74.1 11.3 
HRV (ms) 29.5 23.1 37.0 29.3 
Notes: SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, 
HRV = heart rate variability. 
* p < .05 
** p < .01 
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Table 5. Number of participants with complete data for each salivary measure 
 
 Obese Non-Obese 
Cortisol (µg/dL) 19 20 
Interlukin-6 (pg/mL) 11 11 
Log10 IgA (mL/min) 19 18 
Log10 Alpha-amylase (U/min) 20 20 
Notes: IgA = immunoglobulin A. 
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Table 6. Group means and standard deviations (SD) for baseline salivary measures 
 
Obese Non-obese  
Mean SD Mean SD 
Cortisol (µg/dL)** .28 .16 .45 .20 
Interlukin-6 (pg/mL) 7.4 5.6 5.5 4.3 
Log10 IgA (mL/min) 2.1 .50 2.1 .42 
Log10 Alpha-amylase (U/min)* 1.6 .58 2.0 .42 
Notes: IgA = immunoglobulin A. 
* p < .05 
** p < .01 
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Table 7. ANCOVA Comparing Cardiovascular Task Reactivity, by Task and Group 
(covarying baseline) 
 
Task (CP or MA) 
 
Group (Obese or Non-obese)  Task*Group 
 
F P  F P  F P 
SBP 0.137 0.713  5.775 0.021  1.126 0.295 
DBP 3.125 0.085  9.308 0.004  0.102 0.751 
HR 0.725 0.400  0.773 0.385  2.640 0.113 
HRV 1.021 0.319  4.381 0.043  0.000 1.000 
Notes: CP = cold pressor, MA = mental arithmetic, SBP = systolic blood pressure, DBP = 
diastolic blood pressure, HR = heart rate, HRV = heart rate variability. 
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Table 8. ANCOVA Comparing Cardiovascular CP Recovery, by Recovery Period (early, 
middle and late) and Group (covarying baseline and reactivity) 
 
Recovery Period  
 
Group (Obese or Non-obese)  Task*Group 
 
F P  F P  F P 
SBP 0.128 0.814  0.551 0.463  0.207 0.743 
DBP 0.051 0.915  1.740 0.196  0.588 0.558 
HR 1.757 0.189  0.062 0.804  1.128 0.316 
HRV 6.376 0.009  0.610 0.440  1.902 0.172 
Notes: CP = cold pressor, SBP = systolic blood pressure, DBP = diastolic blood pressure, 
HR = heart rate, HRV = heart rate variability. 
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Table 9. ANCOVA Comparing Cardiovascular MA Recovery, by Recovery Period 
(early, middle and late) and Group (covarying baseline and reactivity) 
 
Recovery Period 
 
Group (Obese or Non-obese)  Task*Group 
 
F P  F P  F P 
SBP 0.364 0.696  4.230 0.047  0.832 0.440 
DBP 0.974 0.383  0.971 0.331  1.187 0.311 
HR 0.703 0.498  0.342 0.562  0.151 0.860 
HRV 0.307 0.736  0.826 0.369  3.934 0.024 
Notes: MA = mental arithmetic, SBP = systolic blood pressure, DBP = diastolic blood 
pressure, HR = heart rate, HRV = heart rate variability. 
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Table 10. ANOVA Comparing salivary reactivity by task and Group 
 
Task (CP or 
MA) 
 Group (Obese or  
Non-obese)  Task*Group 
 
F P  F P  F P 
Cortisol (µg/dL) 0.217 0.644  2.491 0.123  5.071 0.030 
Interlukin-6 (pg/mL) 0.886 0.361  2.276 0.151  0.816 0.380 
Log10 IgA (mL/min) 1.056 0.311  0.035 0.853  0.148 0.703 
Log10 Alpha-amylase 
(U/min) 
0.007 0.932  0.926 0.342  6.923 0.012 
Notes: CP = cold pressor, MA = mental arithmetic, IL-6 = interleukin – 6, IgA = 
immunoglobulin A, AA = alpha amylase. 
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Table 11. ANCOVA Comparing salivary recovery from the CP task and Group 
(covarying baseline) 
 
Period 
 Group (Obese or 
Non-obese)  Task*Group 
 
F P  F P  F P 
Cortisol (µg/dL) 1.720 0.198  1.077 0.306  10876 0.179 
Interlukin-6 (pg/mL) 3.733 0.069  1.081 0.312  0.439 0.516 
Log10 IgA (mL/min) 3.077 0.088  0.734 0.397  2.116 0.115 
Log10 Alpha-amylase 
(U/min) 
1.791 0.189  0.278 0.601  1.316 0.259 
Notes: CP = cold pressor, IgA = immunoglobulin A. 
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Table 12. ANCOVA Comparing salivary recovery from the MA task and Group 
(covarying baseline) 
 
Period 
 Group (Obese or 
Non-obese)  Task*Group 
 
F P  F P  F P 
Cortisol (µg/dL) 6.921 0.012  2.550 0.119  0.435 0.514 
Interlukin-6 (pg/mL) 3.340 0.086  1.020 0.328  1.659 0.216 
Log10 IgA (mL/min) 6.957 0.012  0.675 0.417  3.439 0.072 
Log10 Alpha-amylase 
(U/min) 
1.851 0.182  0.696 0.410  0.780 0.383 
Notes: MA = mental arithmetic, IgA = immunoglobulin A. 
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Table 13. Correlations between cardiovascular and salivary reactivity scores to the CP 
and MA tasks, separated by group. 
 
Non-obese CP task 
 
 Cortisol 
Reactivity 
Interleukin-6 
Reactivity 
IgA Reactivity Alpha-amylase 
Reactivity 
SBP Reactivity 0.367 -0.193 0.448* 0.132 
DBP Reactivity 0.128 -0.061 0.550* 0.347 
HR Reactivity 0.223 -0.127 0.294 0.221 
HRV  0.143 -0.475 0.311 -0.199 
 
Obese CP task 
 
 Cortisol 
Reactivity 
Interleukin-6 
Reactivity 
IgA Reactivity Alpha-amylase 
Reactivity 
SBP Reactivity 0.495* -0.099 0.326 0.099 
DBP Reactivity 0.148 0.405 0.431 0.171 
HR Reactivity 0.389 -0.016 0.151 -0.287 
HRV  -0.200 0.028 0.001 0.138 
 
Non-obese MA task 
 
 Cortisol 
Reactivity 
Interleukin-6 
Reactivity 
IgA Reactivity Alpha-amylase 
Reactivity 
SBP Reactivity 0.436 -0.035 -0.302 0.261 
DBP Reactivity 0.188 0.451 -0.107 0.152 
HR Reactivity 0.525* 0.204 -0.397 0.081 
HRV  -0.404 -0.010 0.159 0.079 
 
Obese MA task 
 
 Cortisol 
Reactivity 
Interleukin-6 
Reactivity 
IgA Reactivity Alpha-amylase 
Reactivity 
SBP Reactivity 0.389 -0.300 0.180 0.050 
DBP Reactivity 0.164 -0.326 -0.029 -0.118 
HR Reactivity 0.615** -0.058 0.504* 0.201 
HRV  -0.322 -0.123 -0.022 -0.011 
Notes: CP = cold pressor, MA = mental arithmetic, IgA = immunoglobulin A, SBP = 
systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, HRV = heart 
rate variability. 
* p < .05 
** p < .01 
 129 
Figure 1. Cardiovascular levels at baseline, CP and MA separated by group. a) systolic 
blood pressure (SBP), b) diastolic blood pressure (DBP), c) heart rate (HR) and d) heart 
rate variability (HRV). Notes: * = p < 0.05 
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Figure 2. Cardiovascular reactivity to the CP and MA task, separated by group. a) 
systolic blood pressure (SBP), b) diastolic blood pressure (DBP), c) heart rate (HR) and 
d) heart rate variability (HRV). Notes: * = p < 0.05 
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Figure 3. Calculation of blood pressure (BP) and heart rate (HR) recovery. 
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Figure 4. Calculation of heart rate variability (HRV) recovery. 
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Figure 5. Salivary levels at baseline, cold pressor (CP), CP recovery, mental arithmetic 
(MA) and MA recovery. a) cortisol, b) interleukin-6, c) immunoglobulin A, d) alpha 
amylase. Notes: * = p < 0.05 
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c) 
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Figure 6. Reactivity of salivary measures. a) cortisol reactivity to the cold pressor and 
mental arithmetic task, b) interleukin-6 reactivity to the cold pressor and mental 
arithmetic task, c) immunoglobulin A reactivity to the cold pressor and mental arithmetic 
task, d) alpha-amylase reactivity to the cold pressor and mental arithmetic task. Notes: # 
= indicates marginally significant differences. Notes: * = p < 0.05, # = p = 0.051 
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c) 
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Figure 7. Recovery of salivary measures. a) cortisol recovery from cold pressor, b) 
cortisol recovery from mental arithmetic, c) interleukin-6 recovery from cold pressor, d) 
interleukin-6 recovery from mental arithmetic, f) immunoglobulin A recovery from cold 
pressor, g) immunoglobulin A recovery from mental arithmetic, h) alpha-amylase 
recovery from cold pressor, i) alpha-amylase recovery from mental arithmetic. Notes: * = 
p < 0.05 
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